Education/CredentialsPost-Doctoral Fellowship: National Institutes of Health (IPA Clinical Gene Therapy )Fellowship: Mount Sinai Hospital (Medical Oncology)Fellowship : Mount Sinai Hospital (Neoplastic Diseases)Residency: Mount Sinai Hospital (Internal Medicine )Internship: Mount Sinai Hospital (Internal Medicine)Medical Degree: Upstate Medical Center College of MedicineBachelor's Degree: City University of New York (Biology) Board Certifications & LicensesAmerican Board of Internal Medicine (Certification Date: 19850911)American Board of Internal Medicine (Medical Oncology) (Certification Date: 19891107) Contact Information Email morri2j7@ucmail.uc.edu Research InterestsLung, translational research, Phase I and II clinical trials, experimental therapeutics, immune therapy strategies, Hematology Oncology Clinical Interests Hematology and OncologyLung CancerMedical OncologyGallbladder CancerMesotheliomaProstate CancerSarcoma Peer Reviewed Publications Bouvet, Michael; Reid, Tony R; Larson, Chris; Oronsky, Bryan; Carter, Corey; Morris, John C 2019. Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients. Oxford medical case reports, 2019 11, 461-463Rahouma, Mohamed; Baudo, Massimo; Yahia, Maha; Kamel, Mohamed; Gray, Katherine D; Elmously, Adham; Ghaly, Galal; Eldessouki, Ihab; Abouarab, Ahmed; Cheriat, Ali N; Karim, Naglaa Abdel; Mohamed, Abdelrahman; Morris, John; Gaudino, Mario 2019. Pneumonitis as a complication of immune system targeting drugs?-a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials. Journal of thoracic disease, 11 2, 521-534Eldessouki, Ihab; Gaber, Ola; Namad, Tariq; Wang, Jiang; Morris, John C; Abdel Karim, Nagla 2018. Small or Non-Small Cell Lung Cancer Based Therapy for Treatment of Large Cell Neuroendocrine Cancer of The Lung? University of Cincinnati Experience. Journal of oncology, 2018 , 9761826Karim, Nagla Abdel; Schuster, James; Eldessouki, Ihab; Gaber, Ola; Namad, Tariq; Wang, Jiang; Xie, Changchun; Morris, John C 2018. Pulmonary sarcomatoid carcinoma: University of Cincinnati experience. Oncotarget, 9 3, 4102-4108Rahouma, Mohamed; Kamel, Mohamed; Abouarab, Ahmed; Eldessouki, Ihab; Nasar, Abu; Harrison, Sebron; Lee, Benjamin; Shostak, Eugene; Morris, John; Stiles, Brendon; Altorki, Nasser K; Port, Jeffrey L 2018. Lung cancer patients have the highest malignancy-associated suicide rate in USA: a population-based analysis. Ecancermedicalscience, 12 , 859Wise-Draper, Trisha; Sendilnathan, Arun; Palackdharry, Sarah; Pease, Nicholas; Qualtieri, Julianne; Butler, Randall; Sadraei, Nooshin Hashemi; Morris, John C; Patil, Yash; Wilson, Keith; Mark, Jonathan; Casper, Keith; Takiar, Vinita; Lane, Adam; Privette Vinnedge, Lisa 2018. Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in a Case-Control Study of Patients with Head and Neck Squamous Cell Carcinoma. Translational oncology, 11 1, 168-174Haugen, Bryan R; Sawka, Anna M; Alexander, Erik K; Bible, Keith C; Caturegli, Patrizio; Doherty, Gerard M; Mandel, Susan J; Morris, John C; Nassar, Aziza; Pacini, Furio; Schlumberger, Martin; Schuff, Kathryn; Sherman, Steven I; Somerset, Hilary; Sosa, Julie Ann; Steward, David L; Wartofsky, Leonard; Williams, Michelle D 2017. American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid : official journal of the American Thyroid Association, 27 4, 481-483Agarwal, Rishi; Wang, Jiang; Wilson, Keith; Barrett, William; Morris, John C 2016. Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer. Journal of the National Comprehensive Cancer Network : JNCCN, 14 10, 1203-1207Ramlogan-Steel, Charmaine A; Steel, Jason C; Morris, John C 2014. Lung cancer vaccines: current status and future prospects. Translational lung cancer research, 3 1, 46-52Alsidawi, S; Morris, J C; Wikenheiser-Brokamp, K A; Starnes, S L; Karim, N A 2013. Mucoepidermoid carcinoma of the lung: a case report and literature review. Case reports in oncological medicine, 2013 , 625243Starnes, Sandra L; Pathrose, Peterson; Wang, Jiang; Succop, Paul; Morris, John C; Bridges, James; Kupert, Elena Y; Anderson, Marshall 2012. Clinical and molecular predictors of recurrence in stage I non-small cell lung cancer. The Annals of thoracic surgery, 93 5, 1606-12Chen J.;Petrus M.;Bryant B.;Nguyen V.;Goldman C.;Bamford R.;Morris J.;Janik J.;Waldmann T. 12-23-2010. Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic ad Blood, 116 26, 5948-5956Janik J.;Morris J. 12-17-2009. Survivin(g) adult T-cell leukemia/lymphoma ONCOLOGY, 23 14, Yu P.;Steel J.;Zhang M.;Morris J.;Waldmann T. 12-15-2010. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity m Clinical Cancer Research, 16 24, 6019-6028Steel J.C.;Morrison B.J.;Morris J.C. 12-07-2012. Monoclonal antibodies for the treatment of cancer Principles of Molecular Diagnostics and Personalized Cancer Medicine, , 580-593Steel J.;Morrison B.;Mannan P.;Abu-Asab M.;Wildner O.;Miles B.;Yim K.;Ramanan V.;Prince G.;Morris J. 12-05-2007. Immunocompetent syngeneic cotton rat tumor models for the assessment of replication-competent oncoly Virology, 369 1, 131-142Komiya T.;Blumenthal G.M.;DeChowdhury R.;Fioravanti S.;Ballas M.S.;Morris J.;Hornyak T.J.;Wank S.;Hewitt S.M.;Morrow B.;Memmott R.M.;Rajan A.;Dennis P.A. 12-01-2019. A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germ Oncologist, 24 12, 1510-e1265Berzofsky J.;Terabe M.;Trepel J.;Pastan I.;Stroncek D.;Morris J.;Wood L. 12-01-2018. Cancer vaccine strategies: translation from mice to human clinical trials Cancer Immunology, Immunotherapy, 67 12, 1863-1869Berkowitz J.;Janik J.;Stewart D.;Jaffe E.;Stetler-Stevenson M.;Shih J.;Fleisher T.;Turner M.;Urquhart N.;Wharfe G.;Figg W.;Peer C.;Goldman C.;Waldmann T.;Morris J. 12-01-2014. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with a Clinical Immunology, 155 2, 176-187Morris J.;Waldmann T. 12-01-2009. Antibody-based therapy of leukaemia Expert Reviews in Molecular Medicine, 11 , Morrison B.J.;Steel J.C.;Gregory M.;Morris J.C.;Malyguine A.M. 12-01-2009. Genetically modified dendritic cells in cancer immunotherapy Dendritic Cells in Cancer, , 347-363Sharp H.;Morris J.;Van Waes C.;Gius D.;Cooley-Zgela T.;Singh A. 12-01-2008. High incidence of oral dysesthesias on a trial of gefitinib, paclitaxel, and concurrent external bea American Journal of Clinical Oncology: Cancer Clinical Trials, 31 6, 557-560Alesci S.;Abu-Asab M.;Perera S.;Tsokos M.;Morris J.;Pacak K. 12-01-2007. Mitochondrial localization of human recombinant adenovirus: From evolution to gene therapy NeuroImmunoModulation, 14 5, 221-223Van Waes C.;Chang A.A.;Lebowitz P.F.;Druzgal C.H.;Chen Z.;Elsayed Y.A.;Sunwoo J.B.;Rudy S.F.;Morris J.C.;Mitchell J.B.;Camphausen K.;Gius D.;Adams J.;Sausville E.A.;Conley B.A. 12-01-2005. Inhibition of nuclear factor-?B and target genes during combined therapy with proteasome inhibitor b International Journal of Radiation Oncology Biology Physics, 63 5, 1400-1412Lei J.Y.;Wang Y.;Jaffe E.S.;Turner M.L.;Raffeld M.;Sorbara L.;Morris J.;Holland S.M.;Duray P.H. 12-01-2000. Microcystic adnexal carcinoma associated with primary immunodeficiency, recurrent diffuse herpes sim American Journal of Dermatopathology, 22 6, 524-529Morris J.;Waldmann T. 11-20-2000. Advances in interleukin 2 receptor targeted treatment Annals of the Rheumatic Diseases, 59 SUPPL. 1, Pise-Masison C.;Radonovich M.;Dohoney K.;Morris J.;O'Mahony D.;Lee M.;Trepel J.;Waldmann T.;Janik J.;Brady J. 11-17-2009. Gene expression profiling of ATL patients: Compilation of disease-related genes and evidence for TCF Blood, 113 17, 4016-4026Janik J.;Morris J.;Pittaluga S.;McDonald K.;Raffeld M.;Jaffe E.;Grant N.;Gutierrez M.;Waldmann T.;Wilson W. 11-15-2004. Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma Blood, 104 10, 3355-3357Morrison B.;Steel J.;Morris J. 11-13-2012. Sphere Culture of Murine Lung Cancer Cell Lines Are Enriched with Cancer Initiating Cells PLoS ONE, 7 11, Ferris R.L.;Saba N.F.;Gitlitz B.J.;Haddad R.;Sukari A.;Neupane P.;Morris J.C.;Misiukiewicz K.;Bauman J.E.;Fenton M.;Jimeno A.;Adkins D.R.;Schneider C.J.;Sacco A.G.;Shirai K.;Bowles D.W.;Gibson M.;Nwizu T.;Gottardo R.;Manjarrez K.L.;Dietsch G.N.;Kyle Bryan J.;Hershberg R.M.;Cohen E.E.W. 11-01-2018. Effect of adding motolimod to standard combination chemotherapy and cetuximab treatment of patients JAMA Oncology, 4 11, 1583-1588Shurin M.;Gregory M.;Morris J.;Malyguine A. 11-01-2010. Genetically modified dendritic cells in cancer immunotherapy: A better tomorrow? Expert Opinion on Biological Therapy, 10 11, 1539-1553Eisenhofer G.;Huynh T.;Elkahloun A.;Morris J.;Bratslavsky G.;Linehan W.;Zhuang Z.;Balgley B.;Lee C.;Mannelli M.;Lenders J.;Bornstein S.;Pacak K. 11-01-2008. Differential expression of the regulated catecholamine secretory pathway in different hereditary for American Journal of Physiology - Endocrinology and Metabolism, 295 5, Ohta S.;Lai E.W.;Morris J.C.;Bakan D.A.;Klaunberg B.;Cleary S.;Powers J.F.;Tischler A.S.;Abu-Asab M.;Schimel D.;Pacak K. 11-01-2006. MicroCT for high-resolution imaging of ectopic pheochromocytoma tumors in the liver of nude mice International Journal of Cancer, 119 9, 2236-2241Sakai Y.;Morrison B.;Burke J.;Park J.;Terabe M.;Janik J.;Forni G.;Berzofsky J.;Morris J. 11-01-2004. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents dev Cancer Research, 64 21, 8022-8028Wildner O.;Blaese R.;Morris J. 11-01-1999. Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase Human Gene Therapy, 10 16, 2679-2687Vaishampayan U.;Schöffski P.;Ravaud A.;Borel C.;Peguero J.;Chaves J.;Morris J.C.;Kotecki N.;Smakal M.;Zhou D.;Guenther S.;Bajars M.;Gulley J.L. 10-24-2019. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell c Journal for ImmunoTherapy of Cancer, 7 1, Janik J.E.;Morris J.C.;O'Mahony D.;Pittaluga S.;Jaffe E.S.;Redon C.E.;Bonner W.M.;Brechbiel M.W.;Paik C.H.;Whatley M.;Chen C.;Lee J.H.;Fleisher T.A.;Brown M.;White J.D.;Stewart D.M.;Fioravanti S.;Lee C.C.;Goldman C.K.;Bryant B.R.;Junghans R.P.;Carrasquillo J.A.;Worthy T.;Corcoran E.;Conlon K.C.;Waldmann T.A. 10-20-2015. <sup>90</sup>Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% o Proceedings of the National Academy of Sciences of the United States of America, 112 42, 13045-13050Savona M.;Kolibaba K.;Conkling P.;Kingsley E.;Becerra C.;Morris J.;Rifkin R.;Laille E.;Kellerman A.;Ukrainskyj S.;Dong Q.;Skikne B. 10-01-2018. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies American Journal of Hematology, 93 10, 1199-1206 Bryan J.K.; Cohen E.; Dietsch G.N.; Ferris R.L.; Gitlitz B.; Haddad R.; Hershberg R.M.; Manjarrez K.L.; Misiukiewicz K.; Morris J.C.; Neupane P.; Saba N.F.; Sukari A. 10-01-2016. immunotherapy of cancer Active8: A randomized, double-blind, placebo-controlled study of chemotherap Annals of Oncology, 27 , vi573Janik J.;O'Mahony D.;Waldmann T.;Morris J. 09-09-2009. Monoclonal antibody therapy of T cell lymphoma: Single agent trials of anti-CD2 (Siplizumab) and ant Haematologica Meeting Reports, 3 1, 61-68Morrison B.;Morris J.;Steel J. 09-01-2013. Lung cancer-initiating cells: A novel target for cancer therapy Targeted Oncology, 8 3, 159-172Druzgal C.;Chen Z.;Yeh N.;Thomas G.;Ondrey F.;Duffey D.;Vilela R.;Ende K.;McCullagh L.;Rudy S.;Muir C.;Herscher L.;Morris J.;Albert P.;Van Waes C. 09-01-2005. A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeuti Head and Neck, 27 9, 771-784Wildner O.;Morris J. 08-31-2000. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex vi Cancer Research, 60 15, 4167-4174Simone C.B.;Morris J.C.;Stewart D.M.;Urquhart N.E.;Janik J.E.;Kreitman R.J.;Lita E.;Conlon K.;Wharfe G.;Waldmann T.A.;Kaushal A. 08-30-2012. Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lympho Blood, 120 9, 1816-1819Rahouma M.;Kamel M.;Abouarab A.;Eldessouki I.;Nasar A.;Harrison S.;Lee B.;Shostak E.;Morris J.;Stiles B.;Altorki N.K.;Port J.L. 08-16-2018. Lung cancer patients have the highest malignancy-associated suicide rate in USA: A population-based ecancermedicalscience, 12 , Haque S.;Morris J. 08-03-2017. Transforming growth factor-?: A therapeutic target for cancer Human Vaccines and Immunotherapeutics, 13 8, 1741-1750Rixe O.;Puzanov I.;Lo Russo P.M.;Cohen R.B.;Morris J.C.;Olowokure O.O.;Yin J.Y.;Doroumian S.;Shen L.;Olszanski A.J. 08-01-2015. Phase i dose-escalation study of cabazitaxel administered in combination with gemcitabine in patient Anti-Cancer Drugs, 26 7, 785-792Pang Y.;Gara S.;Achyut B.;Li Z.;Yan H.;Day C.;Weiss J.;Trinchieri G.;Morris J.;Yang L. 08-01-2013. TGF-? Signaling in myeloid cells is required for tumor metastasis Cancer Discovery, 3 8, 936-951Larson T.;Hu M.;Janik J.;Nussenblatt R.;Morris J.;Sen H. 08-01-2012. Interleukin-2 receptor targeted therapy of ocular disease of HTLV-1-associated adult T-cell leukemia Ocular Immunology and Inflammation, 20 4, 312-314Stewart D.;Ramanathan R.;Mahanty S.;Fedorko D.;Janik J.;Morris J. 08-01-2011. Disseminated Strongyloides stercoralis infection in HTLV-1-associated adult T-cell leukemia/lymphoma Acta Haematologica, 126 2, 63-67Alesci S.;Perera S.;Lai E.;Kukura C.;Abu-Asab M.;Tsokos M.;Morris J.;Pacak K. 08-01-2007. Adenoviral gene transfer in bovine adrenomedullary and murine pheochromocytoma cells: Potential clin Endocrinology, 148 8, 3900-3907Berzofsky J.;Ahlers J.;Janik J.;Morris J.;Oh S.;Terabe M.;Belyakov I. 08-01-2004. Progress on new vaccine strategies against chronic viral infections Journal of Clinical Investigation, 114 4, 450-462Morgensztern D.;Rose M.;Waqar S.N.;Morris J.;Ma P.C.;Reid T.;Brzezniak C.E.;Zeman K.G.;Padmanabhan A.;Hirth J.A.;I. Spira A.;Trepel J.B.;Padda S.K. 07-30-2019. RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung canc British Journal of Cancer, 121 3, 211-217Waldmann T.A.;Conlon K.C.;Stewart D.M.;Worthy T.Y.A.;Janik J.E.;Fleisher T.A.;Albert P.S.;Figg W.D.;Spencer S.D.;Raffeld M.;Decker J.R.;Goldman C.K.;Bryant B.R.;Petrus M.N.;Creekmore S.P.;Morris J.C. 07-17-2013. Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T Blood, 121 3, 476-484Citrin D.;Mansueti J.;Likhacheva A.;Sciuto L.;Albert P.;Rudy S.;Cooley-Zgela T.;Cotrim A.;Solomon B.;Colevas A.;Russo A.;Morris J.;Herscher L.;Smith S.;Van Waes C. 07-15-2009. Long-Term Outcomes and Toxicity of Concurrent Paclitaxel and Radiotherapy for Locally Advanced Head- International Journal of Radiation Oncology Biology Physics, 74 4, 1040-1046Venkataraman G.;Berkowitz J.;Morris J.;Janik J.;Raffeld M.;Pittaluga S. 07-01-2011. Adult T-cell leukemia/lymphoma with Epstein-Barr virus-positive Hodgkin-like cells Human Pathology, 42 7, 1042-1046Zandvakili I.;Lin Y.;Morris J.;Zheng Y. 06-08-2017. Rho GTPases: Anti-or pro-neoplastic targets? Oncogene, 36 23, 3213-3222Wise-Draper T.;Moorthy G.;Salkeni M.;Karim N.;Thomas H.;Mercer C.;Beg M.;O’Gara S.;Olowokure O.;Fathallah H.;Kozma S.;Thomas G.;Rixe O.;Desai P.;Morris J. 06-01-2017. A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Pat Targeted Oncology, 12 3, 323-332Tembhare P.;Yuan C.;Xi L.;Morris J.;Liewehr D.;Venzon D.;Janik J.;Raffeld M.;Stetler-Stevenson M. 06-01-2011. Flow cytometric immunophenotypic assessment of T-cell clonality by V <inf>?</inf> repert American Journal of Clinical Pathology, 135 6, 890-900Van Waes C.;Allen C.;Citrin D.;Gius D.;Colevas A.;Harold N.;Rudy S.;Nottingham L.;Muir C.;Chen Z.;Singh A.;Dancey J.;Morris J. 06-01-2010. Molecular and Clinical Responses in a Pilot Study of Gefitinib With Paclitaxel and Radiation in Loca International Journal of Radiation Oncology Biology Physics, 77 2, 447-454Morris J.;Janik J. 06-01-2007. Therapeutic immunotoxins for lymphoid malignancies: The end of the beginning Leukemia and Lymphoma, 48 6, 1067-1069Wolkersdörfer G.W.;Morris J.C.;Ehninger G.;Ramsey W.J. 06-01-2004. Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma Journal of Gene Medicine, 6 6, 652-662Morris J. 06-01-2003. Cancer gene therapy: Lessons learned from experiences with chemotherapy Molecular Therapy, 7 6, 717-719Waldmann T.;Morris J. 05-29-2006. Development of Antibodies and Chimeric Molecules for Cancer Immunotherapy Advances in Immunology, 90 , 83-131Rahouma M.;Karim N.A.;Baudo M.;Yahia M.;Kamel M.;Eldessouki I.;Abouarab A.;Saad I.;Elmously A.;Gray K.D.;Ghaly G.;Gaber O.;Kamal M.;A Hassan A.;Rahouma M.;D'Ascenzo F.;Morris J.;Mohamed A.;Girardi L.;Gaudino M. 05-15-2019. Cardiotoxicity with immune system targeting drugs: A meta-analysis of anti-PD/PD-L1 immunotherapy ra Immunotherapy, 11 8, 725-735Chen J.;Petrus M.;Bryant B.R.;Nguyen V.P.;Stamer M.;Goldman C.K.;Bamford R.;Morris J.C.;Janik J.E.;Waldmann T.A. 05-15-2008. Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T Blood, 111 10, 5163-5172Morrison B.;Steel J.;Morris J. 05-01-2013. Immunotherapy in lung cancer: The potential of cancer stem cells in future therapies Future Oncology, 9 5, 623-625Moriyama B.;Henning S.;Childs R.;Holland S.;Anderson V.;Morris J.;Wilson W.;Drusano G.;Walsh T. 05-01-2010. High-dose continuous infusion ?-lactam antibiotics for the treatment of resistant Pseudomonas aerugi Annals of Pharmacotherapy, 44 5, 929-935Morrison B.;Steel J.;Morris J. 04-26-2018. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells BMC Cancer, 18 1, Yu P.;Steel J.;Zhang M.;Morris J.;Waitz R.;Fasso M.;Allison J.;Waldmann T. 04-17-2012. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prost Proceedings of the National Academy of Sciences of the United States of America, 109 16, 6187-6192Kelly R.;Lopez-Chavez A.;Citrin D.;Janik J.;Morris J. 04-06-2011. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin Molecular Cancer, 10 , Pal S.;Forero-Torres A.;Thompson J.;Morris J.;Chhabra S.;Hoimes C.;Vogelzang N.;Boyd T.;Bergerot P.;Adashek J.;Li H.;Yu X.;Gartner E.;Carret A.;Smith D. 04-01-2019. A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma Cancer, 125 7, 1124-1132Shao H.;Yuan C.;Xi L.;Raffeld M.;Morris J.;Janik J.;Stetler-Stevenson M. 04-01-2010. Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma American Journal of Clinical Pathology, 133 4, 592-601Jiang L.;Yuan C.;Hubacheck J.;Janik J.;Wilson W.;Morris J.;Jasper G.;Stetler-Stevenson M. 04-01-2009. Variable CD52 expression in mature T cell and NK cell malignancies: Implications for alemtuzumab the British Journal of Haematology, 145 2, 173-179O'Mahony D.;Morris J.;Stetler-Stevenson M.;Matthews H.;Brown M.;Fleisher T.;Pittaluga S.;Raffeld M.;Albert P.;Reitsma D.;Kaucic K.;Hammershaimb L.;Waldmann T.;Janik J. 04-01-2009. EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, Clinical Cancer Research, 15 7, 2514-2522Pernas F.G.;Allen C.T.;Winters M.E.;Yan B.;Friedman J.;Dabir B.;Saigal K.;Mundinger G.S.;Xu X.;Morris J.C.;Calvo K.R.;Van Waes C.;Chen Z. 04-01-2009. Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to Clinical Cancer Research, 15 7, 2361-2372Morris J.;Waldmann T.;Janik J. 04-01-2008. Receptor-directed therapy of T-cell leukemias and lymphomas Journal of Immunotoxicology, 5 2, 235-248Ohta S.;Lai E.W.;Morris J.C.;Pang A.L.Y.;Watanabe M.;Yazawa H.;Zhang R.;Green J.E.;Chan W.Y.;Sirajuddin P.;Taniguchi S.;Powers J.F.;Tischler A.S.;Pacak K. 04-01-2008. Metastasis-associated gene expression profile of liver and subcutaneous lesions derived from mouse p Molecular Carcinogenesis, 47 4, 245-251Steel J.;Cavanagh H.;Burton M.;Abu-Asab M.;Tsokos M.;Morris J.;Kalle W. 04-01-2007. Increased tumor localization and reduced immune response to adenoviral vector formulated with the li European Journal of Pharmaceutical Sciences, 30 5, 398-405Park J.;Terabe M.;Sakai Y.;Munasinghe J.;Forni G.;Morris J.;Berzofsky J. 04-01-2005. Early role of CD4<sup>+</sup> Th1 cells and antibodies in HER-2 adenovirus vaccine prote Journal of Immunology, 174 7, 4228-4236Lacouture M.;Morris J.;Lawrence D.;Tan A.;Olencki T.;Shapiro G.;Dezube B.;Berzofsky J.;Hsu F.;Guitart J. 03-22-2015. Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming g Cancer Immunology, Immunotherapy, 64 4, 437-446Jong M.;Terabe M.;Steel J.;Forni G.;Sakai Y.;Morris J.;Berzofsky J. 03-15-2008. Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccin Cancer Research, 68 6, 1979-1987Morris J.;Tan A.;Olencki T.;Shapiro G.;Dezube B.;Reiss M.;Hsu F.;Berzofsky J.;Lawrence D. 03-11-2014. Phase I study of GC1008 (Fresolimumab): A human anti-transforming growth factor-beta (TGF?) monoclon PLoS ONE, 9 3, Kelly R.;Morris J. 03-01-2010. Transforming growth factor-beta: A target for cancer therapy Journal of Immunotoxicology, 7 1, 15-26Martiniova L.;Lai E.;Elkahloun A.;Abu-Asab M.;Wickremasinghe A.;Solis D.;Perera S.;Huynh T.;Lubensky I.;Tischler A.;Kvetnansky R.;Alesci S.;Morris J.;Pacak K. 03-01-2009. Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific g Clinical and Experimental Metastasis, 26 3, 239-250O'Mahony D.;Debnath I.;Janik J.;Aisner D.;Jaffe E.;Waldmann T.;Morris J. 03-01-2008. Cardiac involvement with human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia/ly Leukemia and Lymphoma, 49 3, 439-446Burke J.;Morris J. 03-01-2007. Retroviral vectors encoding a reverse transcription-activated transgene efficiently limit expression Molecular Therapy, 15 3, 552-559Okada T.;Caplen N.;Ramsey W.;Onodera M.;Shimazaki K.;Nomoto T.;Ajalli R.;Wildner O.;Morris J.;Kume A.;Hamada H.;Blaese R.;Ozawa K. 03-01-2004. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor ce Journal of Gene Medicine, 6 3, 288-299Ju W.;Zhang M.;Jiang J.K.;Thomas C.J.;Oh U.;Bryant B.R.;Chen J.;Sato N.;Tagaya Y.;Morris J.C.;Janik J.E.;Jacobson S.;Waldmann T.A. 02-10-2011. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T c Blood, 117 6, 1938-1946Morris J.;Ramsey W.;Wildner O.;Muslow H.;Aguilar-Cordova E.;Blaese R. 02-10-2000. A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidi Human Gene Therapy, 11 3, 487-503Sarantopoulos J.;Mita A.C.;Wade J.L.;Morris J.C.;Rixe O.;Mita M.M.;Dedieu J.F.;Wack C.;Kassalow L.;Craig Lockhart A. 02-05-2014. Phase i study of cabazitaxel plus cisplatin in patients with advanced solid tumors: Study to evaluat Cancer Chemotherapy and Pharmacology, 74 6, 1113-1124Sarantopoulos J.;Mita A.C.;He A.;Wade J.L.;Hsueh C.T.;Morris J.C.;Lockhart A.C.;Quinn D.I.;Hwang J.;Mier J.;Zhang W.;Wack C.;Yin J.;Clot P.F.;Rixe O. 02-01-2017. Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escal Cancer Chemotherapy and Pharmacology, 79 2, 339-351Tembhare P.;Yuan C.;Morris J.;Janik J.;Filie A.;Stetler-Stevenson M. 02-01-2012. Flow cytometric immunophenotypic assessment of T-cell clonality by V <inf>?</inf> repert American Journal of Clinical Pathology, 137 2, 220-226Martiniova L.;Perera S.M.;Brouwers F.M.;Alesci S.;Abu-Asab M.;Marvelle A.F.;Kiesewetter D.O.;Thomasson D.;Morris J.C.;Kvetnansky R.;Tischler A.S.;Reynolds J.C.;Fojo A.T.;Pacak K. 02-01-2011. Increased uptake of [<sup>123</sup>I]meta-iodobenzylguanidine, [ <sup>18</sup&g Endocrine-Related Cancer, 18 1, 143-157Steel J.;Ramlogan C.;Yu P.;Sakai Y.;Forni G.;Waldmann T.;Morris J. 02-01-2010. Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through Cancer Research, 70 3, 1072-1081O'Mahony D.;Morris J.;Quinn C.;Gao W.;Wilson W.;Gause B.;Pittaluga S.;Neelapu S.;Brown M.;Fleisher T.;Gulley J.;Schlom J.;Nussenblatt R.;Albert P.;Davis T.;Lowy I.;Petrus M.;Waldmann T.;Janik J. 02-01-2007. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy Clinical Cancer Research, 13 3, 958-964Wildner O.;Blaese R.;Morris J. 01-16-1999. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex viru Cancer Research, 59 2, 410-413Gulati S.;Desai J.;Palackdharry S.M.;Morris J.C.;Zhu Z.;Jandarov R.;Riaz M.K.;Takiar V.;Mierzwa M.;Gutkind J.S.;Molinolo A.;Desai P.B.;Sadraei N.H.;Wise-Draper T.M. 01-15-2020. Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in Cancer, 126 2, 354-362Cohen E.E.W.;Soulières D.;Le Tourneau C.;Dinis J.;Licitra L.;Ahn M.J.;Soria A.;Machiels J.P.;Mach N.;Mehra R.;Burtness B.;Zhang P.;Cheng J.;Swaby R.F.;Harrington K.J.;Acosta-Rivera M.;Adkins D.R.;Aghmesheh M.;Airoldi M.;Aleknavicius E.;Al-Farhat Y.;Algazi A.P.;Almokadem S.;Alyasova A.;Bauman J.R.;Benasso M.;Berrocal A.;Bray V.;Burtness B.A.;Caponigro F.;Castro A.;Cescon T.P.;Chan K.;Chaudhry A.;Chauffert B.;Cohen E.;Csoszi T.;De Boer J.P.;Delord J.P.;Dietz A.;Dinis J.;Dupuis C.;Digue L.;Erfan J.;Escobar Alvarez Y.;Evans M.;Fidler M.J.;Forster M.D.;Friesland S.;Ganti A.K.;Geoffrois L.;Grant C.;Gruenwald V.;Harrington K.;Hoffmann T.;Horvai G.;Inciura A.;Jang R.;Jankowska P.;Jimeno A.;Joseph M.;Juarez Ramiro A.;Karaszewska B.;Kawecki A.;Keilholz U.;Keller U.;Kim S.B.;Kocsis J.;Kotecki N.;Kozloff M.F.;Lambea J.;Landherr L.;Lantsukhay Y.;Lazarev S.A.;Lee L.W.;Lifirenko I.D.;Martincic D.;Matorin O.V.;McGrath M.;Misiukiewicz K.;Morris J.C.;Mufazalov F.F.;Niu J.;Pamoorthy Srinivasan D.;Perez Segura P.;Rauch D.;Ribeiro M.L.;Rodriguez C.;Rolland F.;Russo A.;Ruzsa A.;Sanches F.;Shin S.W.;Shtiveland M.;Soulières D.;Specenier P.;Szekanecz E.;Szota J.;van Herpen C.M.L.;Velez-Cortes H.A. 01-12-2019. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck The Lancet, 393 10167, 156-167Morris J.;Janik J.;White J.;Fleisher T.;Brown M.;Tsudo M.;Goldman C.;Bryant B.;Petrus M.;Top L.;Lee C.;Gao W.;Waldmann T. 01-10-2006. Preclinical and phase I clinical trial of blockade of IL-15 using Mik?1 monoclonal antibody in T cel Proceedings of the National Academy of Sciences of the United States of America, 103 2, 401-406Chen J.;Petrus M.;Bamford R.;Shih J.;Morris J.;Janik J.;Waldmann T. 01-05-2012. Increased serum soluble IL-15R? levels in T-cell large granular lymphocyte leukemia Blood, 119 1, 137-143Abdel-Karim N.;Gaber O.;Eldessouki I.;Bahassi E.M.;Morris J. 01-01-2019. Exosomes as a surrogate marker for autophagy in peripheral blood, correlative data from phase i stud Asian Pacific Journal of Cancer Prevention, 20 12, 3789-3796Gaber O.;Eldessouki I.;Hassan R.;Magdy M.;Morris J.;Karim N. 01-01-2019. Retrospective study of the effect of statins on the outcome of lung cancer patients, University of C Asian Pacific Journal of Cancer Prevention, 20 8, 2391-2396Morrison B.;Abu-Asab M.;Morris J.;Steel J. 01-01-2019. Localization of human recombinant adenoviral vectors to the mitochondria following transduction of h Acta virologica, 63 1, 111-116Rahouma M.;Baudo M.;Yahia M.;Kamel M.;Gray K.D.;Elmously A.;Ghaly G.;Eldessouki I.;Abouarab A.;Cheriat A.N.;Karim N.A.;Mohamed A.;Morris J.;Gaudino M. 01-01-2019. Pneumonitis as a complication of immune system targeting drugs?—a meta-analysis of anti-PD/PD-L1 imm Journal of Thoracic Disease, 11 2, 521-534Eldessouki I.;Gaber O.;Namad T.;Wang J.;Morris J.;Karim N. 01-01-2018. Small or non-small cell lung cancer based therapy for treatment of large cell neuroendocrine cancer Journal of Oncology, 2018 , Karim N.A.;Schuster J.;Eldessouki I.;Gaber O.;Namad T.;Wang J.;Xie C.;Morris J.C. 01-01-2018. Pulmonary sarcomatoid carcinoma: University of Cincinnati experience Oncotarget, 9 3, 4102-4108Wise-Draper T.;Sendilnathan A.;Palackdharry S.;Pease N.;Qualtieri J.;Butler R.;Sadraei N.;Morris J.;Patil Y.;Wilson K.;Mark J.;Casper K.;Takiar V.;Lane A.;Privette Vinnedge L. 01-01-2018. Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in Translational Oncology, 11 1, 168-174Sharma K.;Janik J.E.;O'Mahony D.;Stewart D.;Pittaluga S.;Stetler-Stevenson M.;Jaffe E.S.;Raffeld M.;Fleisher T.A.;Lee C.C.;Steinberg S.M.;Waldmann T.A.;Morris J.C. 01-01-2017. Phase II study of alemtuzumab (CAMPATH-1) in patients with HTLV-1-associated adult T-cell leukemia/l Clinical Cancer Research, 23 1, 35-42Conlon K.C.;Lugli E.;Welles H.C.;Rosenberg S.A.;Fojo A.T.;Morris J.C.;Fleisher T.A.;Dubois S.P.;Perera L.P.;Stewart D.M.;Goldman C.K.;Bryant B.R.;Decker J.M.;Chen J.;Worthy T.A.;Figg W.D.;Peer C.J.;Sneller M.C.;Lane H.C.;Yovandich J.L.;Creekmore S.P.;Roederer M.;Waldmann T.A. 01-01-2015. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine Journal of Clinical Oncology, 33 1, 74-82Palma N.;Morris J.C.;Ali S.M.;Ross J.S.;Pal S.K. 01-01-2015. Exceptional response to pazopanib in a patient with urothelial carcinoma harboring FGFR3 activating European Urology, 68 1, 168-170Van Waes C.;Bian Y.;Allen C.;Morris J.;Chen Z. 01-01-2015. Squamous-cell carcinoma Molecular Oncology: Causes of Cancer and Targets for Treatment, , 686-692Wang Y.;Sui Y.;Kato S.;Hogg A.E.;Steel J.C.;Morris J.C.;Berzofsky J.A. 01-01-2015. Vaginal type-II mucosa is an inductive site for primary CD8<sup>+</sup> T-cell mucosal i Nature Communications, 6 , Ghose A.;Morris J.C.;Breneman J.C.;Essell J.;Wang J.;Benzaquen S. 01-01-2014. Medulloblastoma in an adult with late extraneural metastases to the mediastinum Journal of Investigative Medicine High Impact Case Reports, 2 2, Morris J.;Ramlogan-Steel C.;Yu P.;Black B.;Mannan P.;Allison J.;Waldmann T.;Steel J. 01-01-2014. Vaccination with tumor cells expressing IL-15 and IL-15R inhibits murine breast and prostate cancer Gene Therapy, 21 4, 393-401Ramlogan-Steel C.;Steel J.;Morris J. 01-01-2014. Lung cancer vaccines: Current status and future prospects Translational Lung Cancer Research, 3 1, 46-52Chen J.;Pise-Masison C.;Shih J.;Morris J.;Janik J.;Conlon K.;Keating A.;Waldmann T. 01-01-2013. Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 Blood, 121 11, 2029-2037Steel J.;Di Pasquale G.;Ramlogan C.;Patel V.;Chiorini J.;Morris J. 01-01-2013. Oral vaccination with adeno-associated virus vectors expressing the Neu oncogene inhibits the growth Molecular Therapy, 21 3, 680-687Starnes S.;Pathrose P.;Wang J.;Succop P.;Morris J.;Bridges J.;Kupert E.;Anderson M. 01-01-2012. Clinical and molecular predictors of recurrence in stage i non-small cell lung cancer Annals of Thoracic Surgery, 93 5, 1606-1612Steel J.;Waldmann T.;Morris J. 01-01-2012. Interleukin-15 biology and its therapeutic implications in cancer Trends in Pharmacological Sciences, 33 1, 35-41Vinogradova Y.;Kaplanskaya I.;Samoilova R.;Vorobiev I.;Zingerman B.;Sidorova Y.;Shklovskiy-Kordi N.;Aitova L.;Maryin D.;Morris J.;Varticovski L.;Vorobiev A. 01-01-2012. Clinicopathological features and outcomes of T- and NK-cell lymphomas in european Russia Clinical Medicine Insights: Blood Disorders, 5 , 1-13Lai E.;Joshi B.;Martiniova L.;Dogra R.;Fujisawa T.;Leland P.;De Krijger R.;Lubensky I.;Elkahloun A.;Morris J.;Puri R.;Pacak K. 01-01-2009. Overexpression of interleukin-13 receptor-?2 in neuroendocrine malignant pheochromocytoma: A novel t Journal of Clinical Endocrinology and Metabolism, 94 8, 2952-2957Berzofsky J.;Terabe M.;Oh S.;Belyakov I.;Ahlers J.;Janik J.;Morris J. 01-01-2004. Progress on new vaccine strategies for the immunotherapy and prevention of cancer Journal of Clinical Investigation, 113 11, 1515-1525Lee S.S.;Robinson M.R.;Morris J.C.;Mirtsching B.C.;Shen D.F.;Chan C.C. 01-01-2004. Conjunctival involvement with T-cell prolymphocytic leukemia: Report of a case and review of the lit Survey of Ophthalmology, 49 5, 525-536Wildner O.;Morris J. 01-01-2002. Subcutaneous administration of a replication-competent adenovirus expressing HSV-tk to cotton rats: Human Gene Therapy, 13 1, 101-112Morris J.;Wildner O. 01-01-2000. Therapy of Head and Neck Squamous Cell Carcinoma with an Oncolytic Adenovirus Expressing HSV-tk Molecular Therapy, 1 1, 56-62Wildner O.;Morris J. 01-01-2000. Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses Journal of Gene Medicine, 2 5, 353-360Wildner O.;Morris J.;Vahanian N.;Ford H.;Ramsey W.;Blaese R. 01-01-1999. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of Gene Therapy, 6 1, 57-62Ghose, Abhimanyu; Morris, John C; Breneman, John C; Essell, James; Wang, Jiang; Benzaquen, Sadia . Medulloblastoma in an Adult With Late Extraneural Metastases to the Mediastinum. Journal of investigative medicine high impact case reports, 2 2, 2324709614532798
Research InterestsLung, translational research, Phase I and II clinical trials, experimental therapeutics, immune therapy strategies, Hematology Oncology
Clinical Interests Hematology and OncologyLung CancerMedical OncologyGallbladder CancerMesotheliomaProstate CancerSarcoma
Peer Reviewed Publications Bouvet, Michael; Reid, Tony R; Larson, Chris; Oronsky, Bryan; Carter, Corey; Morris, John C 2019. Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients. Oxford medical case reports, 2019 11, 461-463Rahouma, Mohamed; Baudo, Massimo; Yahia, Maha; Kamel, Mohamed; Gray, Katherine D; Elmously, Adham; Ghaly, Galal; Eldessouki, Ihab; Abouarab, Ahmed; Cheriat, Ali N; Karim, Naglaa Abdel; Mohamed, Abdelrahman; Morris, John; Gaudino, Mario 2019. Pneumonitis as a complication of immune system targeting drugs?-a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials. Journal of thoracic disease, 11 2, 521-534Eldessouki, Ihab; Gaber, Ola; Namad, Tariq; Wang, Jiang; Morris, John C; Abdel Karim, Nagla 2018. Small or Non-Small Cell Lung Cancer Based Therapy for Treatment of Large Cell Neuroendocrine Cancer of The Lung? University of Cincinnati Experience. Journal of oncology, 2018 , 9761826Karim, Nagla Abdel; Schuster, James; Eldessouki, Ihab; Gaber, Ola; Namad, Tariq; Wang, Jiang; Xie, Changchun; Morris, John C 2018. Pulmonary sarcomatoid carcinoma: University of Cincinnati experience. Oncotarget, 9 3, 4102-4108Rahouma, Mohamed; Kamel, Mohamed; Abouarab, Ahmed; Eldessouki, Ihab; Nasar, Abu; Harrison, Sebron; Lee, Benjamin; Shostak, Eugene; Morris, John; Stiles, Brendon; Altorki, Nasser K; Port, Jeffrey L 2018. Lung cancer patients have the highest malignancy-associated suicide rate in USA: a population-based analysis. Ecancermedicalscience, 12 , 859Wise-Draper, Trisha; Sendilnathan, Arun; Palackdharry, Sarah; Pease, Nicholas; Qualtieri, Julianne; Butler, Randall; Sadraei, Nooshin Hashemi; Morris, John C; Patil, Yash; Wilson, Keith; Mark, Jonathan; Casper, Keith; Takiar, Vinita; Lane, Adam; Privette Vinnedge, Lisa 2018. Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in a Case-Control Study of Patients with Head and Neck Squamous Cell Carcinoma. Translational oncology, 11 1, 168-174Haugen, Bryan R; Sawka, Anna M; Alexander, Erik K; Bible, Keith C; Caturegli, Patrizio; Doherty, Gerard M; Mandel, Susan J; Morris, John C; Nassar, Aziza; Pacini, Furio; Schlumberger, Martin; Schuff, Kathryn; Sherman, Steven I; Somerset, Hilary; Sosa, Julie Ann; Steward, David L; Wartofsky, Leonard; Williams, Michelle D 2017. American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid : official journal of the American Thyroid Association, 27 4, 481-483Agarwal, Rishi; Wang, Jiang; Wilson, Keith; Barrett, William; Morris, John C 2016. Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer. Journal of the National Comprehensive Cancer Network : JNCCN, 14 10, 1203-1207Ramlogan-Steel, Charmaine A; Steel, Jason C; Morris, John C 2014. Lung cancer vaccines: current status and future prospects. Translational lung cancer research, 3 1, 46-52Alsidawi, S; Morris, J C; Wikenheiser-Brokamp, K A; Starnes, S L; Karim, N A 2013. Mucoepidermoid carcinoma of the lung: a case report and literature review. Case reports in oncological medicine, 2013 , 625243Starnes, Sandra L; Pathrose, Peterson; Wang, Jiang; Succop, Paul; Morris, John C; Bridges, James; Kupert, Elena Y; Anderson, Marshall 2012. Clinical and molecular predictors of recurrence in stage I non-small cell lung cancer. The Annals of thoracic surgery, 93 5, 1606-12Chen J.;Petrus M.;Bryant B.;Nguyen V.;Goldman C.;Bamford R.;Morris J.;Janik J.;Waldmann T. 12-23-2010. Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic ad Blood, 116 26, 5948-5956Janik J.;Morris J. 12-17-2009. Survivin(g) adult T-cell leukemia/lymphoma ONCOLOGY, 23 14, Yu P.;Steel J.;Zhang M.;Morris J.;Waldmann T. 12-15-2010. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity m Clinical Cancer Research, 16 24, 6019-6028Steel J.C.;Morrison B.J.;Morris J.C. 12-07-2012. Monoclonal antibodies for the treatment of cancer Principles of Molecular Diagnostics and Personalized Cancer Medicine, , 580-593Steel J.;Morrison B.;Mannan P.;Abu-Asab M.;Wildner O.;Miles B.;Yim K.;Ramanan V.;Prince G.;Morris J. 12-05-2007. Immunocompetent syngeneic cotton rat tumor models for the assessment of replication-competent oncoly Virology, 369 1, 131-142Komiya T.;Blumenthal G.M.;DeChowdhury R.;Fioravanti S.;Ballas M.S.;Morris J.;Hornyak T.J.;Wank S.;Hewitt S.M.;Morrow B.;Memmott R.M.;Rajan A.;Dennis P.A. 12-01-2019. A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germ Oncologist, 24 12, 1510-e1265Berzofsky J.;Terabe M.;Trepel J.;Pastan I.;Stroncek D.;Morris J.;Wood L. 12-01-2018. Cancer vaccine strategies: translation from mice to human clinical trials Cancer Immunology, Immunotherapy, 67 12, 1863-1869Berkowitz J.;Janik J.;Stewart D.;Jaffe E.;Stetler-Stevenson M.;Shih J.;Fleisher T.;Turner M.;Urquhart N.;Wharfe G.;Figg W.;Peer C.;Goldman C.;Waldmann T.;Morris J. 12-01-2014. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with a Clinical Immunology, 155 2, 176-187Morris J.;Waldmann T. 12-01-2009. Antibody-based therapy of leukaemia Expert Reviews in Molecular Medicine, 11 , Morrison B.J.;Steel J.C.;Gregory M.;Morris J.C.;Malyguine A.M. 12-01-2009. Genetically modified dendritic cells in cancer immunotherapy Dendritic Cells in Cancer, , 347-363Sharp H.;Morris J.;Van Waes C.;Gius D.;Cooley-Zgela T.;Singh A. 12-01-2008. High incidence of oral dysesthesias on a trial of gefitinib, paclitaxel, and concurrent external bea American Journal of Clinical Oncology: Cancer Clinical Trials, 31 6, 557-560Alesci S.;Abu-Asab M.;Perera S.;Tsokos M.;Morris J.;Pacak K. 12-01-2007. Mitochondrial localization of human recombinant adenovirus: From evolution to gene therapy NeuroImmunoModulation, 14 5, 221-223Van Waes C.;Chang A.A.;Lebowitz P.F.;Druzgal C.H.;Chen Z.;Elsayed Y.A.;Sunwoo J.B.;Rudy S.F.;Morris J.C.;Mitchell J.B.;Camphausen K.;Gius D.;Adams J.;Sausville E.A.;Conley B.A. 12-01-2005. Inhibition of nuclear factor-?B and target genes during combined therapy with proteasome inhibitor b International Journal of Radiation Oncology Biology Physics, 63 5, 1400-1412Lei J.Y.;Wang Y.;Jaffe E.S.;Turner M.L.;Raffeld M.;Sorbara L.;Morris J.;Holland S.M.;Duray P.H. 12-01-2000. Microcystic adnexal carcinoma associated with primary immunodeficiency, recurrent diffuse herpes sim American Journal of Dermatopathology, 22 6, 524-529Morris J.;Waldmann T. 11-20-2000. Advances in interleukin 2 receptor targeted treatment Annals of the Rheumatic Diseases, 59 SUPPL. 1, Pise-Masison C.;Radonovich M.;Dohoney K.;Morris J.;O'Mahony D.;Lee M.;Trepel J.;Waldmann T.;Janik J.;Brady J. 11-17-2009. Gene expression profiling of ATL patients: Compilation of disease-related genes and evidence for TCF Blood, 113 17, 4016-4026Janik J.;Morris J.;Pittaluga S.;McDonald K.;Raffeld M.;Jaffe E.;Grant N.;Gutierrez M.;Waldmann T.;Wilson W. 11-15-2004. Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma Blood, 104 10, 3355-3357Morrison B.;Steel J.;Morris J. 11-13-2012. Sphere Culture of Murine Lung Cancer Cell Lines Are Enriched with Cancer Initiating Cells PLoS ONE, 7 11, Ferris R.L.;Saba N.F.;Gitlitz B.J.;Haddad R.;Sukari A.;Neupane P.;Morris J.C.;Misiukiewicz K.;Bauman J.E.;Fenton M.;Jimeno A.;Adkins D.R.;Schneider C.J.;Sacco A.G.;Shirai K.;Bowles D.W.;Gibson M.;Nwizu T.;Gottardo R.;Manjarrez K.L.;Dietsch G.N.;Kyle Bryan J.;Hershberg R.M.;Cohen E.E.W. 11-01-2018. Effect of adding motolimod to standard combination chemotherapy and cetuximab treatment of patients JAMA Oncology, 4 11, 1583-1588Shurin M.;Gregory M.;Morris J.;Malyguine A. 11-01-2010. Genetically modified dendritic cells in cancer immunotherapy: A better tomorrow? Expert Opinion on Biological Therapy, 10 11, 1539-1553Eisenhofer G.;Huynh T.;Elkahloun A.;Morris J.;Bratslavsky G.;Linehan W.;Zhuang Z.;Balgley B.;Lee C.;Mannelli M.;Lenders J.;Bornstein S.;Pacak K. 11-01-2008. Differential expression of the regulated catecholamine secretory pathway in different hereditary for American Journal of Physiology - Endocrinology and Metabolism, 295 5, Ohta S.;Lai E.W.;Morris J.C.;Bakan D.A.;Klaunberg B.;Cleary S.;Powers J.F.;Tischler A.S.;Abu-Asab M.;Schimel D.;Pacak K. 11-01-2006. MicroCT for high-resolution imaging of ectopic pheochromocytoma tumors in the liver of nude mice International Journal of Cancer, 119 9, 2236-2241Sakai Y.;Morrison B.;Burke J.;Park J.;Terabe M.;Janik J.;Forni G.;Berzofsky J.;Morris J. 11-01-2004. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents dev Cancer Research, 64 21, 8022-8028Wildner O.;Blaese R.;Morris J. 11-01-1999. Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase Human Gene Therapy, 10 16, 2679-2687Vaishampayan U.;Schöffski P.;Ravaud A.;Borel C.;Peguero J.;Chaves J.;Morris J.C.;Kotecki N.;Smakal M.;Zhou D.;Guenther S.;Bajars M.;Gulley J.L. 10-24-2019. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell c Journal for ImmunoTherapy of Cancer, 7 1, Janik J.E.;Morris J.C.;O'Mahony D.;Pittaluga S.;Jaffe E.S.;Redon C.E.;Bonner W.M.;Brechbiel M.W.;Paik C.H.;Whatley M.;Chen C.;Lee J.H.;Fleisher T.A.;Brown M.;White J.D.;Stewart D.M.;Fioravanti S.;Lee C.C.;Goldman C.K.;Bryant B.R.;Junghans R.P.;Carrasquillo J.A.;Worthy T.;Corcoran E.;Conlon K.C.;Waldmann T.A. 10-20-2015. <sup>90</sup>Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% o Proceedings of the National Academy of Sciences of the United States of America, 112 42, 13045-13050Savona M.;Kolibaba K.;Conkling P.;Kingsley E.;Becerra C.;Morris J.;Rifkin R.;Laille E.;Kellerman A.;Ukrainskyj S.;Dong Q.;Skikne B. 10-01-2018. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies American Journal of Hematology, 93 10, 1199-1206 Bryan J.K.; Cohen E.; Dietsch G.N.; Ferris R.L.; Gitlitz B.; Haddad R.; Hershberg R.M.; Manjarrez K.L.; Misiukiewicz K.; Morris J.C.; Neupane P.; Saba N.F.; Sukari A. 10-01-2016. immunotherapy of cancer Active8: A randomized, double-blind, placebo-controlled study of chemotherap Annals of Oncology, 27 , vi573Janik J.;O'Mahony D.;Waldmann T.;Morris J. 09-09-2009. Monoclonal antibody therapy of T cell lymphoma: Single agent trials of anti-CD2 (Siplizumab) and ant Haematologica Meeting Reports, 3 1, 61-68Morrison B.;Morris J.;Steel J. 09-01-2013. Lung cancer-initiating cells: A novel target for cancer therapy Targeted Oncology, 8 3, 159-172Druzgal C.;Chen Z.;Yeh N.;Thomas G.;Ondrey F.;Duffey D.;Vilela R.;Ende K.;McCullagh L.;Rudy S.;Muir C.;Herscher L.;Morris J.;Albert P.;Van Waes C. 09-01-2005. A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeuti Head and Neck, 27 9, 771-784Wildner O.;Morris J. 08-31-2000. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex vi Cancer Research, 60 15, 4167-4174Simone C.B.;Morris J.C.;Stewart D.M.;Urquhart N.E.;Janik J.E.;Kreitman R.J.;Lita E.;Conlon K.;Wharfe G.;Waldmann T.A.;Kaushal A. 08-30-2012. Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lympho Blood, 120 9, 1816-1819Rahouma M.;Kamel M.;Abouarab A.;Eldessouki I.;Nasar A.;Harrison S.;Lee B.;Shostak E.;Morris J.;Stiles B.;Altorki N.K.;Port J.L. 08-16-2018. Lung cancer patients have the highest malignancy-associated suicide rate in USA: A population-based ecancermedicalscience, 12 , Haque S.;Morris J. 08-03-2017. Transforming growth factor-?: A therapeutic target for cancer Human Vaccines and Immunotherapeutics, 13 8, 1741-1750Rixe O.;Puzanov I.;Lo Russo P.M.;Cohen R.B.;Morris J.C.;Olowokure O.O.;Yin J.Y.;Doroumian S.;Shen L.;Olszanski A.J. 08-01-2015. Phase i dose-escalation study of cabazitaxel administered in combination with gemcitabine in patient Anti-Cancer Drugs, 26 7, 785-792Pang Y.;Gara S.;Achyut B.;Li Z.;Yan H.;Day C.;Weiss J.;Trinchieri G.;Morris J.;Yang L. 08-01-2013. TGF-? Signaling in myeloid cells is required for tumor metastasis Cancer Discovery, 3 8, 936-951Larson T.;Hu M.;Janik J.;Nussenblatt R.;Morris J.;Sen H. 08-01-2012. Interleukin-2 receptor targeted therapy of ocular disease of HTLV-1-associated adult T-cell leukemia Ocular Immunology and Inflammation, 20 4, 312-314Stewart D.;Ramanathan R.;Mahanty S.;Fedorko D.;Janik J.;Morris J. 08-01-2011. Disseminated Strongyloides stercoralis infection in HTLV-1-associated adult T-cell leukemia/lymphoma Acta Haematologica, 126 2, 63-67Alesci S.;Perera S.;Lai E.;Kukura C.;Abu-Asab M.;Tsokos M.;Morris J.;Pacak K. 08-01-2007. Adenoviral gene transfer in bovine adrenomedullary and murine pheochromocytoma cells: Potential clin Endocrinology, 148 8, 3900-3907Berzofsky J.;Ahlers J.;Janik J.;Morris J.;Oh S.;Terabe M.;Belyakov I. 08-01-2004. Progress on new vaccine strategies against chronic viral infections Journal of Clinical Investigation, 114 4, 450-462Morgensztern D.;Rose M.;Waqar S.N.;Morris J.;Ma P.C.;Reid T.;Brzezniak C.E.;Zeman K.G.;Padmanabhan A.;Hirth J.A.;I. Spira A.;Trepel J.B.;Padda S.K. 07-30-2019. RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung canc British Journal of Cancer, 121 3, 211-217Waldmann T.A.;Conlon K.C.;Stewart D.M.;Worthy T.Y.A.;Janik J.E.;Fleisher T.A.;Albert P.S.;Figg W.D.;Spencer S.D.;Raffeld M.;Decker J.R.;Goldman C.K.;Bryant B.R.;Petrus M.N.;Creekmore S.P.;Morris J.C. 07-17-2013. Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T Blood, 121 3, 476-484Citrin D.;Mansueti J.;Likhacheva A.;Sciuto L.;Albert P.;Rudy S.;Cooley-Zgela T.;Cotrim A.;Solomon B.;Colevas A.;Russo A.;Morris J.;Herscher L.;Smith S.;Van Waes C. 07-15-2009. Long-Term Outcomes and Toxicity of Concurrent Paclitaxel and Radiotherapy for Locally Advanced Head- International Journal of Radiation Oncology Biology Physics, 74 4, 1040-1046Venkataraman G.;Berkowitz J.;Morris J.;Janik J.;Raffeld M.;Pittaluga S. 07-01-2011. Adult T-cell leukemia/lymphoma with Epstein-Barr virus-positive Hodgkin-like cells Human Pathology, 42 7, 1042-1046Zandvakili I.;Lin Y.;Morris J.;Zheng Y. 06-08-2017. Rho GTPases: Anti-or pro-neoplastic targets? Oncogene, 36 23, 3213-3222Wise-Draper T.;Moorthy G.;Salkeni M.;Karim N.;Thomas H.;Mercer C.;Beg M.;O’Gara S.;Olowokure O.;Fathallah H.;Kozma S.;Thomas G.;Rixe O.;Desai P.;Morris J. 06-01-2017. A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Pat Targeted Oncology, 12 3, 323-332Tembhare P.;Yuan C.;Xi L.;Morris J.;Liewehr D.;Venzon D.;Janik J.;Raffeld M.;Stetler-Stevenson M. 06-01-2011. Flow cytometric immunophenotypic assessment of T-cell clonality by V <inf>?</inf> repert American Journal of Clinical Pathology, 135 6, 890-900Van Waes C.;Allen C.;Citrin D.;Gius D.;Colevas A.;Harold N.;Rudy S.;Nottingham L.;Muir C.;Chen Z.;Singh A.;Dancey J.;Morris J. 06-01-2010. Molecular and Clinical Responses in a Pilot Study of Gefitinib With Paclitaxel and Radiation in Loca International Journal of Radiation Oncology Biology Physics, 77 2, 447-454Morris J.;Janik J. 06-01-2007. Therapeutic immunotoxins for lymphoid malignancies: The end of the beginning Leukemia and Lymphoma, 48 6, 1067-1069Wolkersdörfer G.W.;Morris J.C.;Ehninger G.;Ramsey W.J. 06-01-2004. Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma Journal of Gene Medicine, 6 6, 652-662Morris J. 06-01-2003. Cancer gene therapy: Lessons learned from experiences with chemotherapy Molecular Therapy, 7 6, 717-719Waldmann T.;Morris J. 05-29-2006. Development of Antibodies and Chimeric Molecules for Cancer Immunotherapy Advances in Immunology, 90 , 83-131Rahouma M.;Karim N.A.;Baudo M.;Yahia M.;Kamel M.;Eldessouki I.;Abouarab A.;Saad I.;Elmously A.;Gray K.D.;Ghaly G.;Gaber O.;Kamal M.;A Hassan A.;Rahouma M.;D'Ascenzo F.;Morris J.;Mohamed A.;Girardi L.;Gaudino M. 05-15-2019. Cardiotoxicity with immune system targeting drugs: A meta-analysis of anti-PD/PD-L1 immunotherapy ra Immunotherapy, 11 8, 725-735Chen J.;Petrus M.;Bryant B.R.;Nguyen V.P.;Stamer M.;Goldman C.K.;Bamford R.;Morris J.C.;Janik J.E.;Waldmann T.A. 05-15-2008. Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T Blood, 111 10, 5163-5172Morrison B.;Steel J.;Morris J. 05-01-2013. Immunotherapy in lung cancer: The potential of cancer stem cells in future therapies Future Oncology, 9 5, 623-625Moriyama B.;Henning S.;Childs R.;Holland S.;Anderson V.;Morris J.;Wilson W.;Drusano G.;Walsh T. 05-01-2010. High-dose continuous infusion ?-lactam antibiotics for the treatment of resistant Pseudomonas aerugi Annals of Pharmacotherapy, 44 5, 929-935Morrison B.;Steel J.;Morris J. 04-26-2018. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells BMC Cancer, 18 1, Yu P.;Steel J.;Zhang M.;Morris J.;Waitz R.;Fasso M.;Allison J.;Waldmann T. 04-17-2012. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prost Proceedings of the National Academy of Sciences of the United States of America, 109 16, 6187-6192Kelly R.;Lopez-Chavez A.;Citrin D.;Janik J.;Morris J. 04-06-2011. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin Molecular Cancer, 10 , Pal S.;Forero-Torres A.;Thompson J.;Morris J.;Chhabra S.;Hoimes C.;Vogelzang N.;Boyd T.;Bergerot P.;Adashek J.;Li H.;Yu X.;Gartner E.;Carret A.;Smith D. 04-01-2019. A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma Cancer, 125 7, 1124-1132Shao H.;Yuan C.;Xi L.;Raffeld M.;Morris J.;Janik J.;Stetler-Stevenson M. 04-01-2010. Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma American Journal of Clinical Pathology, 133 4, 592-601Jiang L.;Yuan C.;Hubacheck J.;Janik J.;Wilson W.;Morris J.;Jasper G.;Stetler-Stevenson M. 04-01-2009. Variable CD52 expression in mature T cell and NK cell malignancies: Implications for alemtuzumab the British Journal of Haematology, 145 2, 173-179O'Mahony D.;Morris J.;Stetler-Stevenson M.;Matthews H.;Brown M.;Fleisher T.;Pittaluga S.;Raffeld M.;Albert P.;Reitsma D.;Kaucic K.;Hammershaimb L.;Waldmann T.;Janik J. 04-01-2009. EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, Clinical Cancer Research, 15 7, 2514-2522Pernas F.G.;Allen C.T.;Winters M.E.;Yan B.;Friedman J.;Dabir B.;Saigal K.;Mundinger G.S.;Xu X.;Morris J.C.;Calvo K.R.;Van Waes C.;Chen Z. 04-01-2009. Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to Clinical Cancer Research, 15 7, 2361-2372Morris J.;Waldmann T.;Janik J. 04-01-2008. Receptor-directed therapy of T-cell leukemias and lymphomas Journal of Immunotoxicology, 5 2, 235-248Ohta S.;Lai E.W.;Morris J.C.;Pang A.L.Y.;Watanabe M.;Yazawa H.;Zhang R.;Green J.E.;Chan W.Y.;Sirajuddin P.;Taniguchi S.;Powers J.F.;Tischler A.S.;Pacak K. 04-01-2008. Metastasis-associated gene expression profile of liver and subcutaneous lesions derived from mouse p Molecular Carcinogenesis, 47 4, 245-251Steel J.;Cavanagh H.;Burton M.;Abu-Asab M.;Tsokos M.;Morris J.;Kalle W. 04-01-2007. Increased tumor localization and reduced immune response to adenoviral vector formulated with the li European Journal of Pharmaceutical Sciences, 30 5, 398-405Park J.;Terabe M.;Sakai Y.;Munasinghe J.;Forni G.;Morris J.;Berzofsky J. 04-01-2005. Early role of CD4<sup>+</sup> Th1 cells and antibodies in HER-2 adenovirus vaccine prote Journal of Immunology, 174 7, 4228-4236Lacouture M.;Morris J.;Lawrence D.;Tan A.;Olencki T.;Shapiro G.;Dezube B.;Berzofsky J.;Hsu F.;Guitart J. 03-22-2015. Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming g Cancer Immunology, Immunotherapy, 64 4, 437-446Jong M.;Terabe M.;Steel J.;Forni G.;Sakai Y.;Morris J.;Berzofsky J. 03-15-2008. Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccin Cancer Research, 68 6, 1979-1987Morris J.;Tan A.;Olencki T.;Shapiro G.;Dezube B.;Reiss M.;Hsu F.;Berzofsky J.;Lawrence D. 03-11-2014. Phase I study of GC1008 (Fresolimumab): A human anti-transforming growth factor-beta (TGF?) monoclon PLoS ONE, 9 3, Kelly R.;Morris J. 03-01-2010. Transforming growth factor-beta: A target for cancer therapy Journal of Immunotoxicology, 7 1, 15-26Martiniova L.;Lai E.;Elkahloun A.;Abu-Asab M.;Wickremasinghe A.;Solis D.;Perera S.;Huynh T.;Lubensky I.;Tischler A.;Kvetnansky R.;Alesci S.;Morris J.;Pacak K. 03-01-2009. Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific g Clinical and Experimental Metastasis, 26 3, 239-250O'Mahony D.;Debnath I.;Janik J.;Aisner D.;Jaffe E.;Waldmann T.;Morris J. 03-01-2008. Cardiac involvement with human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia/ly Leukemia and Lymphoma, 49 3, 439-446Burke J.;Morris J. 03-01-2007. Retroviral vectors encoding a reverse transcription-activated transgene efficiently limit expression Molecular Therapy, 15 3, 552-559Okada T.;Caplen N.;Ramsey W.;Onodera M.;Shimazaki K.;Nomoto T.;Ajalli R.;Wildner O.;Morris J.;Kume A.;Hamada H.;Blaese R.;Ozawa K. 03-01-2004. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor ce Journal of Gene Medicine, 6 3, 288-299Ju W.;Zhang M.;Jiang J.K.;Thomas C.J.;Oh U.;Bryant B.R.;Chen J.;Sato N.;Tagaya Y.;Morris J.C.;Janik J.E.;Jacobson S.;Waldmann T.A. 02-10-2011. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T c Blood, 117 6, 1938-1946Morris J.;Ramsey W.;Wildner O.;Muslow H.;Aguilar-Cordova E.;Blaese R. 02-10-2000. A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidi Human Gene Therapy, 11 3, 487-503Sarantopoulos J.;Mita A.C.;Wade J.L.;Morris J.C.;Rixe O.;Mita M.M.;Dedieu J.F.;Wack C.;Kassalow L.;Craig Lockhart A. 02-05-2014. Phase i study of cabazitaxel plus cisplatin in patients with advanced solid tumors: Study to evaluat Cancer Chemotherapy and Pharmacology, 74 6, 1113-1124Sarantopoulos J.;Mita A.C.;He A.;Wade J.L.;Hsueh C.T.;Morris J.C.;Lockhart A.C.;Quinn D.I.;Hwang J.;Mier J.;Zhang W.;Wack C.;Yin J.;Clot P.F.;Rixe O. 02-01-2017. Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escal Cancer Chemotherapy and Pharmacology, 79 2, 339-351Tembhare P.;Yuan C.;Morris J.;Janik J.;Filie A.;Stetler-Stevenson M. 02-01-2012. Flow cytometric immunophenotypic assessment of T-cell clonality by V <inf>?</inf> repert American Journal of Clinical Pathology, 137 2, 220-226Martiniova L.;Perera S.M.;Brouwers F.M.;Alesci S.;Abu-Asab M.;Marvelle A.F.;Kiesewetter D.O.;Thomasson D.;Morris J.C.;Kvetnansky R.;Tischler A.S.;Reynolds J.C.;Fojo A.T.;Pacak K. 02-01-2011. Increased uptake of [<sup>123</sup>I]meta-iodobenzylguanidine, [ <sup>18</sup&g Endocrine-Related Cancer, 18 1, 143-157Steel J.;Ramlogan C.;Yu P.;Sakai Y.;Forni G.;Waldmann T.;Morris J. 02-01-2010. Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through Cancer Research, 70 3, 1072-1081O'Mahony D.;Morris J.;Quinn C.;Gao W.;Wilson W.;Gause B.;Pittaluga S.;Neelapu S.;Brown M.;Fleisher T.;Gulley J.;Schlom J.;Nussenblatt R.;Albert P.;Davis T.;Lowy I.;Petrus M.;Waldmann T.;Janik J. 02-01-2007. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy Clinical Cancer Research, 13 3, 958-964Wildner O.;Blaese R.;Morris J. 01-16-1999. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex viru Cancer Research, 59 2, 410-413Gulati S.;Desai J.;Palackdharry S.M.;Morris J.C.;Zhu Z.;Jandarov R.;Riaz M.K.;Takiar V.;Mierzwa M.;Gutkind J.S.;Molinolo A.;Desai P.B.;Sadraei N.H.;Wise-Draper T.M. 01-15-2020. Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in Cancer, 126 2, 354-362Cohen E.E.W.;Soulières D.;Le Tourneau C.;Dinis J.;Licitra L.;Ahn M.J.;Soria A.;Machiels J.P.;Mach N.;Mehra R.;Burtness B.;Zhang P.;Cheng J.;Swaby R.F.;Harrington K.J.;Acosta-Rivera M.;Adkins D.R.;Aghmesheh M.;Airoldi M.;Aleknavicius E.;Al-Farhat Y.;Algazi A.P.;Almokadem S.;Alyasova A.;Bauman J.R.;Benasso M.;Berrocal A.;Bray V.;Burtness B.A.;Caponigro F.;Castro A.;Cescon T.P.;Chan K.;Chaudhry A.;Chauffert B.;Cohen E.;Csoszi T.;De Boer J.P.;Delord J.P.;Dietz A.;Dinis J.;Dupuis C.;Digue L.;Erfan J.;Escobar Alvarez Y.;Evans M.;Fidler M.J.;Forster M.D.;Friesland S.;Ganti A.K.;Geoffrois L.;Grant C.;Gruenwald V.;Harrington K.;Hoffmann T.;Horvai G.;Inciura A.;Jang R.;Jankowska P.;Jimeno A.;Joseph M.;Juarez Ramiro A.;Karaszewska B.;Kawecki A.;Keilholz U.;Keller U.;Kim S.B.;Kocsis J.;Kotecki N.;Kozloff M.F.;Lambea J.;Landherr L.;Lantsukhay Y.;Lazarev S.A.;Lee L.W.;Lifirenko I.D.;Martincic D.;Matorin O.V.;McGrath M.;Misiukiewicz K.;Morris J.C.;Mufazalov F.F.;Niu J.;Pamoorthy Srinivasan D.;Perez Segura P.;Rauch D.;Ribeiro M.L.;Rodriguez C.;Rolland F.;Russo A.;Ruzsa A.;Sanches F.;Shin S.W.;Shtiveland M.;Soulières D.;Specenier P.;Szekanecz E.;Szota J.;van Herpen C.M.L.;Velez-Cortes H.A. 01-12-2019. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck The Lancet, 393 10167, 156-167Morris J.;Janik J.;White J.;Fleisher T.;Brown M.;Tsudo M.;Goldman C.;Bryant B.;Petrus M.;Top L.;Lee C.;Gao W.;Waldmann T. 01-10-2006. Preclinical and phase I clinical trial of blockade of IL-15 using Mik?1 monoclonal antibody in T cel Proceedings of the National Academy of Sciences of the United States of America, 103 2, 401-406Chen J.;Petrus M.;Bamford R.;Shih J.;Morris J.;Janik J.;Waldmann T. 01-05-2012. Increased serum soluble IL-15R? levels in T-cell large granular lymphocyte leukemia Blood, 119 1, 137-143Abdel-Karim N.;Gaber O.;Eldessouki I.;Bahassi E.M.;Morris J. 01-01-2019. Exosomes as a surrogate marker for autophagy in peripheral blood, correlative data from phase i stud Asian Pacific Journal of Cancer Prevention, 20 12, 3789-3796Gaber O.;Eldessouki I.;Hassan R.;Magdy M.;Morris J.;Karim N. 01-01-2019. Retrospective study of the effect of statins on the outcome of lung cancer patients, University of C Asian Pacific Journal of Cancer Prevention, 20 8, 2391-2396Morrison B.;Abu-Asab M.;Morris J.;Steel J. 01-01-2019. Localization of human recombinant adenoviral vectors to the mitochondria following transduction of h Acta virologica, 63 1, 111-116Rahouma M.;Baudo M.;Yahia M.;Kamel M.;Gray K.D.;Elmously A.;Ghaly G.;Eldessouki I.;Abouarab A.;Cheriat A.N.;Karim N.A.;Mohamed A.;Morris J.;Gaudino M. 01-01-2019. Pneumonitis as a complication of immune system targeting drugs?—a meta-analysis of anti-PD/PD-L1 imm Journal of Thoracic Disease, 11 2, 521-534Eldessouki I.;Gaber O.;Namad T.;Wang J.;Morris J.;Karim N. 01-01-2018. Small or non-small cell lung cancer based therapy for treatment of large cell neuroendocrine cancer Journal of Oncology, 2018 , Karim N.A.;Schuster J.;Eldessouki I.;Gaber O.;Namad T.;Wang J.;Xie C.;Morris J.C. 01-01-2018. Pulmonary sarcomatoid carcinoma: University of Cincinnati experience Oncotarget, 9 3, 4102-4108Wise-Draper T.;Sendilnathan A.;Palackdharry S.;Pease N.;Qualtieri J.;Butler R.;Sadraei N.;Morris J.;Patil Y.;Wilson K.;Mark J.;Casper K.;Takiar V.;Lane A.;Privette Vinnedge L. 01-01-2018. Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in Translational Oncology, 11 1, 168-174Sharma K.;Janik J.E.;O'Mahony D.;Stewart D.;Pittaluga S.;Stetler-Stevenson M.;Jaffe E.S.;Raffeld M.;Fleisher T.A.;Lee C.C.;Steinberg S.M.;Waldmann T.A.;Morris J.C. 01-01-2017. Phase II study of alemtuzumab (CAMPATH-1) in patients with HTLV-1-associated adult T-cell leukemia/l Clinical Cancer Research, 23 1, 35-42Conlon K.C.;Lugli E.;Welles H.C.;Rosenberg S.A.;Fojo A.T.;Morris J.C.;Fleisher T.A.;Dubois S.P.;Perera L.P.;Stewart D.M.;Goldman C.K.;Bryant B.R.;Decker J.M.;Chen J.;Worthy T.A.;Figg W.D.;Peer C.J.;Sneller M.C.;Lane H.C.;Yovandich J.L.;Creekmore S.P.;Roederer M.;Waldmann T.A. 01-01-2015. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine Journal of Clinical Oncology, 33 1, 74-82Palma N.;Morris J.C.;Ali S.M.;Ross J.S.;Pal S.K. 01-01-2015. Exceptional response to pazopanib in a patient with urothelial carcinoma harboring FGFR3 activating European Urology, 68 1, 168-170Van Waes C.;Bian Y.;Allen C.;Morris J.;Chen Z. 01-01-2015. Squamous-cell carcinoma Molecular Oncology: Causes of Cancer and Targets for Treatment, , 686-692Wang Y.;Sui Y.;Kato S.;Hogg A.E.;Steel J.C.;Morris J.C.;Berzofsky J.A. 01-01-2015. Vaginal type-II mucosa is an inductive site for primary CD8<sup>+</sup> T-cell mucosal i Nature Communications, 6 , Ghose A.;Morris J.C.;Breneman J.C.;Essell J.;Wang J.;Benzaquen S. 01-01-2014. Medulloblastoma in an adult with late extraneural metastases to the mediastinum Journal of Investigative Medicine High Impact Case Reports, 2 2, Morris J.;Ramlogan-Steel C.;Yu P.;Black B.;Mannan P.;Allison J.;Waldmann T.;Steel J. 01-01-2014. Vaccination with tumor cells expressing IL-15 and IL-15R inhibits murine breast and prostate cancer Gene Therapy, 21 4, 393-401Ramlogan-Steel C.;Steel J.;Morris J. 01-01-2014. Lung cancer vaccines: Current status and future prospects Translational Lung Cancer Research, 3 1, 46-52Chen J.;Pise-Masison C.;Shih J.;Morris J.;Janik J.;Conlon K.;Keating A.;Waldmann T. 01-01-2013. Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 Blood, 121 11, 2029-2037Steel J.;Di Pasquale G.;Ramlogan C.;Patel V.;Chiorini J.;Morris J. 01-01-2013. Oral vaccination with adeno-associated virus vectors expressing the Neu oncogene inhibits the growth Molecular Therapy, 21 3, 680-687Starnes S.;Pathrose P.;Wang J.;Succop P.;Morris J.;Bridges J.;Kupert E.;Anderson M. 01-01-2012. Clinical and molecular predictors of recurrence in stage i non-small cell lung cancer Annals of Thoracic Surgery, 93 5, 1606-1612Steel J.;Waldmann T.;Morris J. 01-01-2012. Interleukin-15 biology and its therapeutic implications in cancer Trends in Pharmacological Sciences, 33 1, 35-41Vinogradova Y.;Kaplanskaya I.;Samoilova R.;Vorobiev I.;Zingerman B.;Sidorova Y.;Shklovskiy-Kordi N.;Aitova L.;Maryin D.;Morris J.;Varticovski L.;Vorobiev A. 01-01-2012. Clinicopathological features and outcomes of T- and NK-cell lymphomas in european Russia Clinical Medicine Insights: Blood Disorders, 5 , 1-13Lai E.;Joshi B.;Martiniova L.;Dogra R.;Fujisawa T.;Leland P.;De Krijger R.;Lubensky I.;Elkahloun A.;Morris J.;Puri R.;Pacak K. 01-01-2009. Overexpression of interleukin-13 receptor-?2 in neuroendocrine malignant pheochromocytoma: A novel t Journal of Clinical Endocrinology and Metabolism, 94 8, 2952-2957Berzofsky J.;Terabe M.;Oh S.;Belyakov I.;Ahlers J.;Janik J.;Morris J. 01-01-2004. Progress on new vaccine strategies for the immunotherapy and prevention of cancer Journal of Clinical Investigation, 113 11, 1515-1525Lee S.S.;Robinson M.R.;Morris J.C.;Mirtsching B.C.;Shen D.F.;Chan C.C. 01-01-2004. Conjunctival involvement with T-cell prolymphocytic leukemia: Report of a case and review of the lit Survey of Ophthalmology, 49 5, 525-536Wildner O.;Morris J. 01-01-2002. Subcutaneous administration of a replication-competent adenovirus expressing HSV-tk to cotton rats: Human Gene Therapy, 13 1, 101-112Morris J.;Wildner O. 01-01-2000. Therapy of Head and Neck Squamous Cell Carcinoma with an Oncolytic Adenovirus Expressing HSV-tk Molecular Therapy, 1 1, 56-62Wildner O.;Morris J. 01-01-2000. Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses Journal of Gene Medicine, 2 5, 353-360Wildner O.;Morris J.;Vahanian N.;Ford H.;Ramsey W.;Blaese R. 01-01-1999. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of Gene Therapy, 6 1, 57-62Ghose, Abhimanyu; Morris, John C; Breneman, John C; Essell, James; Wang, Jiang; Benzaquen, Sadia . Medulloblastoma in an Adult With Late Extraneural Metastases to the Mediastinum. Journal of investigative medicine high impact case reports, 2 2, 2324709614532798
Bouvet, Michael; Reid, Tony R; Larson, Chris; Oronsky, Bryan; Carter, Corey; Morris, John C 2019. Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients. Oxford medical case reports, 2019 11, 461-463Rahouma, Mohamed; Baudo, Massimo; Yahia, Maha; Kamel, Mohamed; Gray, Katherine D; Elmously, Adham; Ghaly, Galal; Eldessouki, Ihab; Abouarab, Ahmed; Cheriat, Ali N; Karim, Naglaa Abdel; Mohamed, Abdelrahman; Morris, John; Gaudino, Mario 2019. Pneumonitis as a complication of immune system targeting drugs?-a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials. Journal of thoracic disease, 11 2, 521-534Eldessouki, Ihab; Gaber, Ola; Namad, Tariq; Wang, Jiang; Morris, John C; Abdel Karim, Nagla 2018. Small or Non-Small Cell Lung Cancer Based Therapy for Treatment of Large Cell Neuroendocrine Cancer of The Lung? University of Cincinnati Experience. Journal of oncology, 2018 , 9761826Karim, Nagla Abdel; Schuster, James; Eldessouki, Ihab; Gaber, Ola; Namad, Tariq; Wang, Jiang; Xie, Changchun; Morris, John C 2018. Pulmonary sarcomatoid carcinoma: University of Cincinnati experience. Oncotarget, 9 3, 4102-4108Rahouma, Mohamed; Kamel, Mohamed; Abouarab, Ahmed; Eldessouki, Ihab; Nasar, Abu; Harrison, Sebron; Lee, Benjamin; Shostak, Eugene; Morris, John; Stiles, Brendon; Altorki, Nasser K; Port, Jeffrey L 2018. Lung cancer patients have the highest malignancy-associated suicide rate in USA: a population-based analysis. Ecancermedicalscience, 12 , 859Wise-Draper, Trisha; Sendilnathan, Arun; Palackdharry, Sarah; Pease, Nicholas; Qualtieri, Julianne; Butler, Randall; Sadraei, Nooshin Hashemi; Morris, John C; Patil, Yash; Wilson, Keith; Mark, Jonathan; Casper, Keith; Takiar, Vinita; Lane, Adam; Privette Vinnedge, Lisa 2018. Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in a Case-Control Study of Patients with Head and Neck Squamous Cell Carcinoma. Translational oncology, 11 1, 168-174Haugen, Bryan R; Sawka, Anna M; Alexander, Erik K; Bible, Keith C; Caturegli, Patrizio; Doherty, Gerard M; Mandel, Susan J; Morris, John C; Nassar, Aziza; Pacini, Furio; Schlumberger, Martin; Schuff, Kathryn; Sherman, Steven I; Somerset, Hilary; Sosa, Julie Ann; Steward, David L; Wartofsky, Leonard; Williams, Michelle D 2017. American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid : official journal of the American Thyroid Association, 27 4, 481-483Agarwal, Rishi; Wang, Jiang; Wilson, Keith; Barrett, William; Morris, John C 2016. Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer. Journal of the National Comprehensive Cancer Network : JNCCN, 14 10, 1203-1207Ramlogan-Steel, Charmaine A; Steel, Jason C; Morris, John C 2014. Lung cancer vaccines: current status and future prospects. Translational lung cancer research, 3 1, 46-52Alsidawi, S; Morris, J C; Wikenheiser-Brokamp, K A; Starnes, S L; Karim, N A 2013. Mucoepidermoid carcinoma of the lung: a case report and literature review. Case reports in oncological medicine, 2013 , 625243Starnes, Sandra L; Pathrose, Peterson; Wang, Jiang; Succop, Paul; Morris, John C; Bridges, James; Kupert, Elena Y; Anderson, Marshall 2012. Clinical and molecular predictors of recurrence in stage I non-small cell lung cancer. The Annals of thoracic surgery, 93 5, 1606-12Chen J.;Petrus M.;Bryant B.;Nguyen V.;Goldman C.;Bamford R.;Morris J.;Janik J.;Waldmann T. 12-23-2010. Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic ad Blood, 116 26, 5948-5956Janik J.;Morris J. 12-17-2009. Survivin(g) adult T-cell leukemia/lymphoma ONCOLOGY, 23 14, Yu P.;Steel J.;Zhang M.;Morris J.;Waldmann T. 12-15-2010. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity m Clinical Cancer Research, 16 24, 6019-6028Steel J.C.;Morrison B.J.;Morris J.C. 12-07-2012. Monoclonal antibodies for the treatment of cancer Principles of Molecular Diagnostics and Personalized Cancer Medicine, , 580-593Steel J.;Morrison B.;Mannan P.;Abu-Asab M.;Wildner O.;Miles B.;Yim K.;Ramanan V.;Prince G.;Morris J. 12-05-2007. Immunocompetent syngeneic cotton rat tumor models for the assessment of replication-competent oncoly Virology, 369 1, 131-142Komiya T.;Blumenthal G.M.;DeChowdhury R.;Fioravanti S.;Ballas M.S.;Morris J.;Hornyak T.J.;Wank S.;Hewitt S.M.;Morrow B.;Memmott R.M.;Rajan A.;Dennis P.A. 12-01-2019. A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germ Oncologist, 24 12, 1510-e1265Berzofsky J.;Terabe M.;Trepel J.;Pastan I.;Stroncek D.;Morris J.;Wood L. 12-01-2018. Cancer vaccine strategies: translation from mice to human clinical trials Cancer Immunology, Immunotherapy, 67 12, 1863-1869Berkowitz J.;Janik J.;Stewart D.;Jaffe E.;Stetler-Stevenson M.;Shih J.;Fleisher T.;Turner M.;Urquhart N.;Wharfe G.;Figg W.;Peer C.;Goldman C.;Waldmann T.;Morris J. 12-01-2014. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with a Clinical Immunology, 155 2, 176-187Morris J.;Waldmann T. 12-01-2009. Antibody-based therapy of leukaemia Expert Reviews in Molecular Medicine, 11 , Morrison B.J.;Steel J.C.;Gregory M.;Morris J.C.;Malyguine A.M. 12-01-2009. Genetically modified dendritic cells in cancer immunotherapy Dendritic Cells in Cancer, , 347-363Sharp H.;Morris J.;Van Waes C.;Gius D.;Cooley-Zgela T.;Singh A. 12-01-2008. High incidence of oral dysesthesias on a trial of gefitinib, paclitaxel, and concurrent external bea American Journal of Clinical Oncology: Cancer Clinical Trials, 31 6, 557-560Alesci S.;Abu-Asab M.;Perera S.;Tsokos M.;Morris J.;Pacak K. 12-01-2007. Mitochondrial localization of human recombinant adenovirus: From evolution to gene therapy NeuroImmunoModulation, 14 5, 221-223Van Waes C.;Chang A.A.;Lebowitz P.F.;Druzgal C.H.;Chen Z.;Elsayed Y.A.;Sunwoo J.B.;Rudy S.F.;Morris J.C.;Mitchell J.B.;Camphausen K.;Gius D.;Adams J.;Sausville E.A.;Conley B.A. 12-01-2005. Inhibition of nuclear factor-?B and target genes during combined therapy with proteasome inhibitor b International Journal of Radiation Oncology Biology Physics, 63 5, 1400-1412Lei J.Y.;Wang Y.;Jaffe E.S.;Turner M.L.;Raffeld M.;Sorbara L.;Morris J.;Holland S.M.;Duray P.H. 12-01-2000. Microcystic adnexal carcinoma associated with primary immunodeficiency, recurrent diffuse herpes sim American Journal of Dermatopathology, 22 6, 524-529Morris J.;Waldmann T. 11-20-2000. Advances in interleukin 2 receptor targeted treatment Annals of the Rheumatic Diseases, 59 SUPPL. 1, Pise-Masison C.;Radonovich M.;Dohoney K.;Morris J.;O'Mahony D.;Lee M.;Trepel J.;Waldmann T.;Janik J.;Brady J. 11-17-2009. Gene expression profiling of ATL patients: Compilation of disease-related genes and evidence for TCF Blood, 113 17, 4016-4026Janik J.;Morris J.;Pittaluga S.;McDonald K.;Raffeld M.;Jaffe E.;Grant N.;Gutierrez M.;Waldmann T.;Wilson W. 11-15-2004. Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma Blood, 104 10, 3355-3357Morrison B.;Steel J.;Morris J. 11-13-2012. Sphere Culture of Murine Lung Cancer Cell Lines Are Enriched with Cancer Initiating Cells PLoS ONE, 7 11, Ferris R.L.;Saba N.F.;Gitlitz B.J.;Haddad R.;Sukari A.;Neupane P.;Morris J.C.;Misiukiewicz K.;Bauman J.E.;Fenton M.;Jimeno A.;Adkins D.R.;Schneider C.J.;Sacco A.G.;Shirai K.;Bowles D.W.;Gibson M.;Nwizu T.;Gottardo R.;Manjarrez K.L.;Dietsch G.N.;Kyle Bryan J.;Hershberg R.M.;Cohen E.E.W. 11-01-2018. Effect of adding motolimod to standard combination chemotherapy and cetuximab treatment of patients JAMA Oncology, 4 11, 1583-1588Shurin M.;Gregory M.;Morris J.;Malyguine A. 11-01-2010. Genetically modified dendritic cells in cancer immunotherapy: A better tomorrow? Expert Opinion on Biological Therapy, 10 11, 1539-1553Eisenhofer G.;Huynh T.;Elkahloun A.;Morris J.;Bratslavsky G.;Linehan W.;Zhuang Z.;Balgley B.;Lee C.;Mannelli M.;Lenders J.;Bornstein S.;Pacak K. 11-01-2008. Differential expression of the regulated catecholamine secretory pathway in different hereditary for American Journal of Physiology - Endocrinology and Metabolism, 295 5, Ohta S.;Lai E.W.;Morris J.C.;Bakan D.A.;Klaunberg B.;Cleary S.;Powers J.F.;Tischler A.S.;Abu-Asab M.;Schimel D.;Pacak K. 11-01-2006. MicroCT for high-resolution imaging of ectopic pheochromocytoma tumors in the liver of nude mice International Journal of Cancer, 119 9, 2236-2241Sakai Y.;Morrison B.;Burke J.;Park J.;Terabe M.;Janik J.;Forni G.;Berzofsky J.;Morris J. 11-01-2004. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents dev Cancer Research, 64 21, 8022-8028Wildner O.;Blaese R.;Morris J. 11-01-1999. Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase Human Gene Therapy, 10 16, 2679-2687Vaishampayan U.;Schöffski P.;Ravaud A.;Borel C.;Peguero J.;Chaves J.;Morris J.C.;Kotecki N.;Smakal M.;Zhou D.;Guenther S.;Bajars M.;Gulley J.L. 10-24-2019. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell c Journal for ImmunoTherapy of Cancer, 7 1, Janik J.E.;Morris J.C.;O'Mahony D.;Pittaluga S.;Jaffe E.S.;Redon C.E.;Bonner W.M.;Brechbiel M.W.;Paik C.H.;Whatley M.;Chen C.;Lee J.H.;Fleisher T.A.;Brown M.;White J.D.;Stewart D.M.;Fioravanti S.;Lee C.C.;Goldman C.K.;Bryant B.R.;Junghans R.P.;Carrasquillo J.A.;Worthy T.;Corcoran E.;Conlon K.C.;Waldmann T.A. 10-20-2015. <sup>90</sup>Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% o Proceedings of the National Academy of Sciences of the United States of America, 112 42, 13045-13050Savona M.;Kolibaba K.;Conkling P.;Kingsley E.;Becerra C.;Morris J.;Rifkin R.;Laille E.;Kellerman A.;Ukrainskyj S.;Dong Q.;Skikne B. 10-01-2018. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies American Journal of Hematology, 93 10, 1199-1206 Bryan J.K.; Cohen E.; Dietsch G.N.; Ferris R.L.; Gitlitz B.; Haddad R.; Hershberg R.M.; Manjarrez K.L.; Misiukiewicz K.; Morris J.C.; Neupane P.; Saba N.F.; Sukari A. 10-01-2016. immunotherapy of cancer Active8: A randomized, double-blind, placebo-controlled study of chemotherap Annals of Oncology, 27 , vi573Janik J.;O'Mahony D.;Waldmann T.;Morris J. 09-09-2009. Monoclonal antibody therapy of T cell lymphoma: Single agent trials of anti-CD2 (Siplizumab) and ant Haematologica Meeting Reports, 3 1, 61-68Morrison B.;Morris J.;Steel J. 09-01-2013. Lung cancer-initiating cells: A novel target for cancer therapy Targeted Oncology, 8 3, 159-172Druzgal C.;Chen Z.;Yeh N.;Thomas G.;Ondrey F.;Duffey D.;Vilela R.;Ende K.;McCullagh L.;Rudy S.;Muir C.;Herscher L.;Morris J.;Albert P.;Van Waes C. 09-01-2005. A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeuti Head and Neck, 27 9, 771-784Wildner O.;Morris J. 08-31-2000. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex vi Cancer Research, 60 15, 4167-4174Simone C.B.;Morris J.C.;Stewart D.M.;Urquhart N.E.;Janik J.E.;Kreitman R.J.;Lita E.;Conlon K.;Wharfe G.;Waldmann T.A.;Kaushal A. 08-30-2012. Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lympho Blood, 120 9, 1816-1819Rahouma M.;Kamel M.;Abouarab A.;Eldessouki I.;Nasar A.;Harrison S.;Lee B.;Shostak E.;Morris J.;Stiles B.;Altorki N.K.;Port J.L. 08-16-2018. Lung cancer patients have the highest malignancy-associated suicide rate in USA: A population-based ecancermedicalscience, 12 , Haque S.;Morris J. 08-03-2017. Transforming growth factor-?: A therapeutic target for cancer Human Vaccines and Immunotherapeutics, 13 8, 1741-1750Rixe O.;Puzanov I.;Lo Russo P.M.;Cohen R.B.;Morris J.C.;Olowokure O.O.;Yin J.Y.;Doroumian S.;Shen L.;Olszanski A.J. 08-01-2015. Phase i dose-escalation study of cabazitaxel administered in combination with gemcitabine in patient Anti-Cancer Drugs, 26 7, 785-792Pang Y.;Gara S.;Achyut B.;Li Z.;Yan H.;Day C.;Weiss J.;Trinchieri G.;Morris J.;Yang L. 08-01-2013. TGF-? Signaling in myeloid cells is required for tumor metastasis Cancer Discovery, 3 8, 936-951Larson T.;Hu M.;Janik J.;Nussenblatt R.;Morris J.;Sen H. 08-01-2012. Interleukin-2 receptor targeted therapy of ocular disease of HTLV-1-associated adult T-cell leukemia Ocular Immunology and Inflammation, 20 4, 312-314Stewart D.;Ramanathan R.;Mahanty S.;Fedorko D.;Janik J.;Morris J. 08-01-2011. Disseminated Strongyloides stercoralis infection in HTLV-1-associated adult T-cell leukemia/lymphoma Acta Haematologica, 126 2, 63-67Alesci S.;Perera S.;Lai E.;Kukura C.;Abu-Asab M.;Tsokos M.;Morris J.;Pacak K. 08-01-2007. Adenoviral gene transfer in bovine adrenomedullary and murine pheochromocytoma cells: Potential clin Endocrinology, 148 8, 3900-3907Berzofsky J.;Ahlers J.;Janik J.;Morris J.;Oh S.;Terabe M.;Belyakov I. 08-01-2004. Progress on new vaccine strategies against chronic viral infections Journal of Clinical Investigation, 114 4, 450-462Morgensztern D.;Rose M.;Waqar S.N.;Morris J.;Ma P.C.;Reid T.;Brzezniak C.E.;Zeman K.G.;Padmanabhan A.;Hirth J.A.;I. Spira A.;Trepel J.B.;Padda S.K. 07-30-2019. RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung canc British Journal of Cancer, 121 3, 211-217Waldmann T.A.;Conlon K.C.;Stewart D.M.;Worthy T.Y.A.;Janik J.E.;Fleisher T.A.;Albert P.S.;Figg W.D.;Spencer S.D.;Raffeld M.;Decker J.R.;Goldman C.K.;Bryant B.R.;Petrus M.N.;Creekmore S.P.;Morris J.C. 07-17-2013. Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T Blood, 121 3, 476-484Citrin D.;Mansueti J.;Likhacheva A.;Sciuto L.;Albert P.;Rudy S.;Cooley-Zgela T.;Cotrim A.;Solomon B.;Colevas A.;Russo A.;Morris J.;Herscher L.;Smith S.;Van Waes C. 07-15-2009. Long-Term Outcomes and Toxicity of Concurrent Paclitaxel and Radiotherapy for Locally Advanced Head- International Journal of Radiation Oncology Biology Physics, 74 4, 1040-1046Venkataraman G.;Berkowitz J.;Morris J.;Janik J.;Raffeld M.;Pittaluga S. 07-01-2011. Adult T-cell leukemia/lymphoma with Epstein-Barr virus-positive Hodgkin-like cells Human Pathology, 42 7, 1042-1046Zandvakili I.;Lin Y.;Morris J.;Zheng Y. 06-08-2017. Rho GTPases: Anti-or pro-neoplastic targets? Oncogene, 36 23, 3213-3222Wise-Draper T.;Moorthy G.;Salkeni M.;Karim N.;Thomas H.;Mercer C.;Beg M.;O’Gara S.;Olowokure O.;Fathallah H.;Kozma S.;Thomas G.;Rixe O.;Desai P.;Morris J. 06-01-2017. A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Pat Targeted Oncology, 12 3, 323-332Tembhare P.;Yuan C.;Xi L.;Morris J.;Liewehr D.;Venzon D.;Janik J.;Raffeld M.;Stetler-Stevenson M. 06-01-2011. Flow cytometric immunophenotypic assessment of T-cell clonality by V <inf>?</inf> repert American Journal of Clinical Pathology, 135 6, 890-900Van Waes C.;Allen C.;Citrin D.;Gius D.;Colevas A.;Harold N.;Rudy S.;Nottingham L.;Muir C.;Chen Z.;Singh A.;Dancey J.;Morris J. 06-01-2010. Molecular and Clinical Responses in a Pilot Study of Gefitinib With Paclitaxel and Radiation in Loca International Journal of Radiation Oncology Biology Physics, 77 2, 447-454Morris J.;Janik J. 06-01-2007. Therapeutic immunotoxins for lymphoid malignancies: The end of the beginning Leukemia and Lymphoma, 48 6, 1067-1069Wolkersdörfer G.W.;Morris J.C.;Ehninger G.;Ramsey W.J. 06-01-2004. Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma Journal of Gene Medicine, 6 6, 652-662Morris J. 06-01-2003. Cancer gene therapy: Lessons learned from experiences with chemotherapy Molecular Therapy, 7 6, 717-719Waldmann T.;Morris J. 05-29-2006. Development of Antibodies and Chimeric Molecules for Cancer Immunotherapy Advances in Immunology, 90 , 83-131Rahouma M.;Karim N.A.;Baudo M.;Yahia M.;Kamel M.;Eldessouki I.;Abouarab A.;Saad I.;Elmously A.;Gray K.D.;Ghaly G.;Gaber O.;Kamal M.;A Hassan A.;Rahouma M.;D'Ascenzo F.;Morris J.;Mohamed A.;Girardi L.;Gaudino M. 05-15-2019. Cardiotoxicity with immune system targeting drugs: A meta-analysis of anti-PD/PD-L1 immunotherapy ra Immunotherapy, 11 8, 725-735Chen J.;Petrus M.;Bryant B.R.;Nguyen V.P.;Stamer M.;Goldman C.K.;Bamford R.;Morris J.C.;Janik J.E.;Waldmann T.A. 05-15-2008. Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T Blood, 111 10, 5163-5172Morrison B.;Steel J.;Morris J. 05-01-2013. Immunotherapy in lung cancer: The potential of cancer stem cells in future therapies Future Oncology, 9 5, 623-625Moriyama B.;Henning S.;Childs R.;Holland S.;Anderson V.;Morris J.;Wilson W.;Drusano G.;Walsh T. 05-01-2010. High-dose continuous infusion ?-lactam antibiotics for the treatment of resistant Pseudomonas aerugi Annals of Pharmacotherapy, 44 5, 929-935Morrison B.;Steel J.;Morris J. 04-26-2018. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells BMC Cancer, 18 1, Yu P.;Steel J.;Zhang M.;Morris J.;Waitz R.;Fasso M.;Allison J.;Waldmann T. 04-17-2012. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prost Proceedings of the National Academy of Sciences of the United States of America, 109 16, 6187-6192Kelly R.;Lopez-Chavez A.;Citrin D.;Janik J.;Morris J. 04-06-2011. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin Molecular Cancer, 10 , Pal S.;Forero-Torres A.;Thompson J.;Morris J.;Chhabra S.;Hoimes C.;Vogelzang N.;Boyd T.;Bergerot P.;Adashek J.;Li H.;Yu X.;Gartner E.;Carret A.;Smith D. 04-01-2019. A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma Cancer, 125 7, 1124-1132Shao H.;Yuan C.;Xi L.;Raffeld M.;Morris J.;Janik J.;Stetler-Stevenson M. 04-01-2010. Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma American Journal of Clinical Pathology, 133 4, 592-601Jiang L.;Yuan C.;Hubacheck J.;Janik J.;Wilson W.;Morris J.;Jasper G.;Stetler-Stevenson M. 04-01-2009. Variable CD52 expression in mature T cell and NK cell malignancies: Implications for alemtuzumab the British Journal of Haematology, 145 2, 173-179O'Mahony D.;Morris J.;Stetler-Stevenson M.;Matthews H.;Brown M.;Fleisher T.;Pittaluga S.;Raffeld M.;Albert P.;Reitsma D.;Kaucic K.;Hammershaimb L.;Waldmann T.;Janik J. 04-01-2009. EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, Clinical Cancer Research, 15 7, 2514-2522Pernas F.G.;Allen C.T.;Winters M.E.;Yan B.;Friedman J.;Dabir B.;Saigal K.;Mundinger G.S.;Xu X.;Morris J.C.;Calvo K.R.;Van Waes C.;Chen Z. 04-01-2009. Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to Clinical Cancer Research, 15 7, 2361-2372Morris J.;Waldmann T.;Janik J. 04-01-2008. Receptor-directed therapy of T-cell leukemias and lymphomas Journal of Immunotoxicology, 5 2, 235-248Ohta S.;Lai E.W.;Morris J.C.;Pang A.L.Y.;Watanabe M.;Yazawa H.;Zhang R.;Green J.E.;Chan W.Y.;Sirajuddin P.;Taniguchi S.;Powers J.F.;Tischler A.S.;Pacak K. 04-01-2008. Metastasis-associated gene expression profile of liver and subcutaneous lesions derived from mouse p Molecular Carcinogenesis, 47 4, 245-251Steel J.;Cavanagh H.;Burton M.;Abu-Asab M.;Tsokos M.;Morris J.;Kalle W. 04-01-2007. Increased tumor localization and reduced immune response to adenoviral vector formulated with the li European Journal of Pharmaceutical Sciences, 30 5, 398-405Park J.;Terabe M.;Sakai Y.;Munasinghe J.;Forni G.;Morris J.;Berzofsky J. 04-01-2005. Early role of CD4<sup>+</sup> Th1 cells and antibodies in HER-2 adenovirus vaccine prote Journal of Immunology, 174 7, 4228-4236Lacouture M.;Morris J.;Lawrence D.;Tan A.;Olencki T.;Shapiro G.;Dezube B.;Berzofsky J.;Hsu F.;Guitart J. 03-22-2015. Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming g Cancer Immunology, Immunotherapy, 64 4, 437-446Jong M.;Terabe M.;Steel J.;Forni G.;Sakai Y.;Morris J.;Berzofsky J. 03-15-2008. Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccin Cancer Research, 68 6, 1979-1987Morris J.;Tan A.;Olencki T.;Shapiro G.;Dezube B.;Reiss M.;Hsu F.;Berzofsky J.;Lawrence D. 03-11-2014. Phase I study of GC1008 (Fresolimumab): A human anti-transforming growth factor-beta (TGF?) monoclon PLoS ONE, 9 3, Kelly R.;Morris J. 03-01-2010. Transforming growth factor-beta: A target for cancer therapy Journal of Immunotoxicology, 7 1, 15-26Martiniova L.;Lai E.;Elkahloun A.;Abu-Asab M.;Wickremasinghe A.;Solis D.;Perera S.;Huynh T.;Lubensky I.;Tischler A.;Kvetnansky R.;Alesci S.;Morris J.;Pacak K. 03-01-2009. Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific g Clinical and Experimental Metastasis, 26 3, 239-250O'Mahony D.;Debnath I.;Janik J.;Aisner D.;Jaffe E.;Waldmann T.;Morris J. 03-01-2008. Cardiac involvement with human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia/ly Leukemia and Lymphoma, 49 3, 439-446Burke J.;Morris J. 03-01-2007. Retroviral vectors encoding a reverse transcription-activated transgene efficiently limit expression Molecular Therapy, 15 3, 552-559Okada T.;Caplen N.;Ramsey W.;Onodera M.;Shimazaki K.;Nomoto T.;Ajalli R.;Wildner O.;Morris J.;Kume A.;Hamada H.;Blaese R.;Ozawa K. 03-01-2004. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor ce Journal of Gene Medicine, 6 3, 288-299Ju W.;Zhang M.;Jiang J.K.;Thomas C.J.;Oh U.;Bryant B.R.;Chen J.;Sato N.;Tagaya Y.;Morris J.C.;Janik J.E.;Jacobson S.;Waldmann T.A. 02-10-2011. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T c Blood, 117 6, 1938-1946Morris J.;Ramsey W.;Wildner O.;Muslow H.;Aguilar-Cordova E.;Blaese R. 02-10-2000. A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidi Human Gene Therapy, 11 3, 487-503Sarantopoulos J.;Mita A.C.;Wade J.L.;Morris J.C.;Rixe O.;Mita M.M.;Dedieu J.F.;Wack C.;Kassalow L.;Craig Lockhart A. 02-05-2014. Phase i study of cabazitaxel plus cisplatin in patients with advanced solid tumors: Study to evaluat Cancer Chemotherapy and Pharmacology, 74 6, 1113-1124Sarantopoulos J.;Mita A.C.;He A.;Wade J.L.;Hsueh C.T.;Morris J.C.;Lockhart A.C.;Quinn D.I.;Hwang J.;Mier J.;Zhang W.;Wack C.;Yin J.;Clot P.F.;Rixe O. 02-01-2017. Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escal Cancer Chemotherapy and Pharmacology, 79 2, 339-351Tembhare P.;Yuan C.;Morris J.;Janik J.;Filie A.;Stetler-Stevenson M. 02-01-2012. Flow cytometric immunophenotypic assessment of T-cell clonality by V <inf>?</inf> repert American Journal of Clinical Pathology, 137 2, 220-226Martiniova L.;Perera S.M.;Brouwers F.M.;Alesci S.;Abu-Asab M.;Marvelle A.F.;Kiesewetter D.O.;Thomasson D.;Morris J.C.;Kvetnansky R.;Tischler A.S.;Reynolds J.C.;Fojo A.T.;Pacak K. 02-01-2011. Increased uptake of [<sup>123</sup>I]meta-iodobenzylguanidine, [ <sup>18</sup&g Endocrine-Related Cancer, 18 1, 143-157Steel J.;Ramlogan C.;Yu P.;Sakai Y.;Forni G.;Waldmann T.;Morris J. 02-01-2010. Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through Cancer Research, 70 3, 1072-1081O'Mahony D.;Morris J.;Quinn C.;Gao W.;Wilson W.;Gause B.;Pittaluga S.;Neelapu S.;Brown M.;Fleisher T.;Gulley J.;Schlom J.;Nussenblatt R.;Albert P.;Davis T.;Lowy I.;Petrus M.;Waldmann T.;Janik J. 02-01-2007. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy Clinical Cancer Research, 13 3, 958-964Wildner O.;Blaese R.;Morris J. 01-16-1999. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex viru Cancer Research, 59 2, 410-413Gulati S.;Desai J.;Palackdharry S.M.;Morris J.C.;Zhu Z.;Jandarov R.;Riaz M.K.;Takiar V.;Mierzwa M.;Gutkind J.S.;Molinolo A.;Desai P.B.;Sadraei N.H.;Wise-Draper T.M. 01-15-2020. Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in Cancer, 126 2, 354-362Cohen E.E.W.;Soulières D.;Le Tourneau C.;Dinis J.;Licitra L.;Ahn M.J.;Soria A.;Machiels J.P.;Mach N.;Mehra R.;Burtness B.;Zhang P.;Cheng J.;Swaby R.F.;Harrington K.J.;Acosta-Rivera M.;Adkins D.R.;Aghmesheh M.;Airoldi M.;Aleknavicius E.;Al-Farhat Y.;Algazi A.P.;Almokadem S.;Alyasova A.;Bauman J.R.;Benasso M.;Berrocal A.;Bray V.;Burtness B.A.;Caponigro F.;Castro A.;Cescon T.P.;Chan K.;Chaudhry A.;Chauffert B.;Cohen E.;Csoszi T.;De Boer J.P.;Delord J.P.;Dietz A.;Dinis J.;Dupuis C.;Digue L.;Erfan J.;Escobar Alvarez Y.;Evans M.;Fidler M.J.;Forster M.D.;Friesland S.;Ganti A.K.;Geoffrois L.;Grant C.;Gruenwald V.;Harrington K.;Hoffmann T.;Horvai G.;Inciura A.;Jang R.;Jankowska P.;Jimeno A.;Joseph M.;Juarez Ramiro A.;Karaszewska B.;Kawecki A.;Keilholz U.;Keller U.;Kim S.B.;Kocsis J.;Kotecki N.;Kozloff M.F.;Lambea J.;Landherr L.;Lantsukhay Y.;Lazarev S.A.;Lee L.W.;Lifirenko I.D.;Martincic D.;Matorin O.V.;McGrath M.;Misiukiewicz K.;Morris J.C.;Mufazalov F.F.;Niu J.;Pamoorthy Srinivasan D.;Perez Segura P.;Rauch D.;Ribeiro M.L.;Rodriguez C.;Rolland F.;Russo A.;Ruzsa A.;Sanches F.;Shin S.W.;Shtiveland M.;Soulières D.;Specenier P.;Szekanecz E.;Szota J.;van Herpen C.M.L.;Velez-Cortes H.A. 01-12-2019. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck The Lancet, 393 10167, 156-167Morris J.;Janik J.;White J.;Fleisher T.;Brown M.;Tsudo M.;Goldman C.;Bryant B.;Petrus M.;Top L.;Lee C.;Gao W.;Waldmann T. 01-10-2006. Preclinical and phase I clinical trial of blockade of IL-15 using Mik?1 monoclonal antibody in T cel Proceedings of the National Academy of Sciences of the United States of America, 103 2, 401-406Chen J.;Petrus M.;Bamford R.;Shih J.;Morris J.;Janik J.;Waldmann T. 01-05-2012. Increased serum soluble IL-15R? levels in T-cell large granular lymphocyte leukemia Blood, 119 1, 137-143Abdel-Karim N.;Gaber O.;Eldessouki I.;Bahassi E.M.;Morris J. 01-01-2019. Exosomes as a surrogate marker for autophagy in peripheral blood, correlative data from phase i stud Asian Pacific Journal of Cancer Prevention, 20 12, 3789-3796Gaber O.;Eldessouki I.;Hassan R.;Magdy M.;Morris J.;Karim N. 01-01-2019. Retrospective study of the effect of statins on the outcome of lung cancer patients, University of C Asian Pacific Journal of Cancer Prevention, 20 8, 2391-2396Morrison B.;Abu-Asab M.;Morris J.;Steel J. 01-01-2019. Localization of human recombinant adenoviral vectors to the mitochondria following transduction of h Acta virologica, 63 1, 111-116Rahouma M.;Baudo M.;Yahia M.;Kamel M.;Gray K.D.;Elmously A.;Ghaly G.;Eldessouki I.;Abouarab A.;Cheriat A.N.;Karim N.A.;Mohamed A.;Morris J.;Gaudino M. 01-01-2019. Pneumonitis as a complication of immune system targeting drugs?—a meta-analysis of anti-PD/PD-L1 imm Journal of Thoracic Disease, 11 2, 521-534Eldessouki I.;Gaber O.;Namad T.;Wang J.;Morris J.;Karim N. 01-01-2018. Small or non-small cell lung cancer based therapy for treatment of large cell neuroendocrine cancer Journal of Oncology, 2018 , Karim N.A.;Schuster J.;Eldessouki I.;Gaber O.;Namad T.;Wang J.;Xie C.;Morris J.C. 01-01-2018. Pulmonary sarcomatoid carcinoma: University of Cincinnati experience Oncotarget, 9 3, 4102-4108Wise-Draper T.;Sendilnathan A.;Palackdharry S.;Pease N.;Qualtieri J.;Butler R.;Sadraei N.;Morris J.;Patil Y.;Wilson K.;Mark J.;Casper K.;Takiar V.;Lane A.;Privette Vinnedge L. 01-01-2018. Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in Translational Oncology, 11 1, 168-174Sharma K.;Janik J.E.;O'Mahony D.;Stewart D.;Pittaluga S.;Stetler-Stevenson M.;Jaffe E.S.;Raffeld M.;Fleisher T.A.;Lee C.C.;Steinberg S.M.;Waldmann T.A.;Morris J.C. 01-01-2017. Phase II study of alemtuzumab (CAMPATH-1) in patients with HTLV-1-associated adult T-cell leukemia/l Clinical Cancer Research, 23 1, 35-42Conlon K.C.;Lugli E.;Welles H.C.;Rosenberg S.A.;Fojo A.T.;Morris J.C.;Fleisher T.A.;Dubois S.P.;Perera L.P.;Stewart D.M.;Goldman C.K.;Bryant B.R.;Decker J.M.;Chen J.;Worthy T.A.;Figg W.D.;Peer C.J.;Sneller M.C.;Lane H.C.;Yovandich J.L.;Creekmore S.P.;Roederer M.;Waldmann T.A. 01-01-2015. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine Journal of Clinical Oncology, 33 1, 74-82Palma N.;Morris J.C.;Ali S.M.;Ross J.S.;Pal S.K. 01-01-2015. Exceptional response to pazopanib in a patient with urothelial carcinoma harboring FGFR3 activating European Urology, 68 1, 168-170Van Waes C.;Bian Y.;Allen C.;Morris J.;Chen Z. 01-01-2015. Squamous-cell carcinoma Molecular Oncology: Causes of Cancer and Targets for Treatment, , 686-692Wang Y.;Sui Y.;Kato S.;Hogg A.E.;Steel J.C.;Morris J.C.;Berzofsky J.A. 01-01-2015. Vaginal type-II mucosa is an inductive site for primary CD8<sup>+</sup> T-cell mucosal i Nature Communications, 6 , Ghose A.;Morris J.C.;Breneman J.C.;Essell J.;Wang J.;Benzaquen S. 01-01-2014. Medulloblastoma in an adult with late extraneural metastases to the mediastinum Journal of Investigative Medicine High Impact Case Reports, 2 2, Morris J.;Ramlogan-Steel C.;Yu P.;Black B.;Mannan P.;Allison J.;Waldmann T.;Steel J. 01-01-2014. Vaccination with tumor cells expressing IL-15 and IL-15R inhibits murine breast and prostate cancer Gene Therapy, 21 4, 393-401Ramlogan-Steel C.;Steel J.;Morris J. 01-01-2014. Lung cancer vaccines: Current status and future prospects Translational Lung Cancer Research, 3 1, 46-52Chen J.;Pise-Masison C.;Shih J.;Morris J.;Janik J.;Conlon K.;Keating A.;Waldmann T. 01-01-2013. Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 Blood, 121 11, 2029-2037Steel J.;Di Pasquale G.;Ramlogan C.;Patel V.;Chiorini J.;Morris J. 01-01-2013. Oral vaccination with adeno-associated virus vectors expressing the Neu oncogene inhibits the growth Molecular Therapy, 21 3, 680-687Starnes S.;Pathrose P.;Wang J.;Succop P.;Morris J.;Bridges J.;Kupert E.;Anderson M. 01-01-2012. Clinical and molecular predictors of recurrence in stage i non-small cell lung cancer Annals of Thoracic Surgery, 93 5, 1606-1612Steel J.;Waldmann T.;Morris J. 01-01-2012. Interleukin-15 biology and its therapeutic implications in cancer Trends in Pharmacological Sciences, 33 1, 35-41Vinogradova Y.;Kaplanskaya I.;Samoilova R.;Vorobiev I.;Zingerman B.;Sidorova Y.;Shklovskiy-Kordi N.;Aitova L.;Maryin D.;Morris J.;Varticovski L.;Vorobiev A. 01-01-2012. Clinicopathological features and outcomes of T- and NK-cell lymphomas in european Russia Clinical Medicine Insights: Blood Disorders, 5 , 1-13Lai E.;Joshi B.;Martiniova L.;Dogra R.;Fujisawa T.;Leland P.;De Krijger R.;Lubensky I.;Elkahloun A.;Morris J.;Puri R.;Pacak K. 01-01-2009. Overexpression of interleukin-13 receptor-?2 in neuroendocrine malignant pheochromocytoma: A novel t Journal of Clinical Endocrinology and Metabolism, 94 8, 2952-2957Berzofsky J.;Terabe M.;Oh S.;Belyakov I.;Ahlers J.;Janik J.;Morris J. 01-01-2004. Progress on new vaccine strategies for the immunotherapy and prevention of cancer Journal of Clinical Investigation, 113 11, 1515-1525Lee S.S.;Robinson M.R.;Morris J.C.;Mirtsching B.C.;Shen D.F.;Chan C.C. 01-01-2004. Conjunctival involvement with T-cell prolymphocytic leukemia: Report of a case and review of the lit Survey of Ophthalmology, 49 5, 525-536Wildner O.;Morris J. 01-01-2002. Subcutaneous administration of a replication-competent adenovirus expressing HSV-tk to cotton rats: Human Gene Therapy, 13 1, 101-112Morris J.;Wildner O. 01-01-2000. Therapy of Head and Neck Squamous Cell Carcinoma with an Oncolytic Adenovirus Expressing HSV-tk Molecular Therapy, 1 1, 56-62Wildner O.;Morris J. 01-01-2000. Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses Journal of Gene Medicine, 2 5, 353-360Wildner O.;Morris J.;Vahanian N.;Ford H.;Ramsey W.;Blaese R. 01-01-1999. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of Gene Therapy, 6 1, 57-62Ghose, Abhimanyu; Morris, John C; Breneman, John C; Essell, James; Wang, Jiang; Benzaquen, Sadia . Medulloblastoma in an Adult With Late Extraneural Metastases to the Mediastinum. Journal of investigative medicine high impact case reports, 2 2, 2324709614532798